

# CITATION REPORT

List of articles citing

## Diabetic Kidney Disease: Challenges, Progress, and Possibilities

DOI: 10.2215/cjn.11491116

Clinical Journal of the American Society of  
Nephrology: CJASN, 2017, 12, 2032-2045.

**Source:** <https://exaly.com/paper-pdf/66389502/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #    | Paper  | IF | Citations |
|------|--|----|-----------|
| 1175 | Will Canagliflozin Lend Credence to the Potential Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Endpoints in Diabetic Nephropathy. <b>2017</b> , 46, 459-461                                      |    | 2         |
| 1174 | What is new in diabetic nephropathy during the last decade?. <b>2017</b> , 12, 386-390   |    |           |
| 1173 | Sensitive albuminuria analysis using dye-binding based test strips. <b>2017</b> , 471, 107-112   |    | 19        |
| 1172 | A new model of diabetic nephropathy in C57BL/6 mice challenged with advanced oxidation protein products. <b>2018</b> , 118, 71-84  |    | 8         |
| 1171 | The relationship between the thickness of glomerular basement membrane and renal outcomes in patients with diabetic nephropathy. <b>2018</b> , 55, 669-679   |    | 13        |
| 1170 | Simultaneous Risk Factor Control Using Telehealth to sLOW Progression of Diabetic Kidney Disease (STOP-DKD) study: Protocol and baseline characteristics of a randomized controlled trial. <b>2018</b> , 69, 28-39 |    | 11        |
| 1169 | Urine mitochondrial DNA and diabetic nephropathy-a new frontier. <b>2018</b> , 33, 719-721   |    |           |
| 1168 | Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease. <b>2018</b> , 3, 804-816   |    | 78        |
| 1167 | The Warburg Effect in Diabetic Kidney Disease. <b>2018</b> , 38, 111-120   |    | 46        |
| 1166 | Implication of decreased serum complement 3 in patients with diabetic nephropathy. <b>2018</b> , 55, 31-39   |    | 9         |
| 1165 | Tyrosines-740/751 of PDGFR $\alpha$ contribute to the activation of Akt/Hif1 $\alpha$ /TGF $\beta$ 1 axis to drive high glucose-induced glomerular mesangial cell hypertrophy. <b>2018</b> , 42, 44-53             |    | 4         |
| 1164 | The ABCs of chronic kidney disease. <b>2018</b> , 31, 17-25  |    | 2         |
| 1163 | New Tubulocentric Insights for Diabetic Nephropathy: From Pathophysiology to Treatment. <b>2018</b> ,  |    | 1         |
| 1162 | 10-Year Renal Function Trajectories in Community-Dwelling Older Adults: Exploring the Risk Factors for Different Patterns. <b>2018</b> , 7,  |    | 1         |
| 1161 | The association between the red cell distribution width and diabetic nephropathy in patients with type-2 diabetes mellitus. <b>2018</b> , 40, 590-596  |    | 10        |
| 1160 | ERp44 depletion exacerbates ER stress and aggravates diabetic nephropathy in db/db mice. <b>2018</b> , 504, 921-926  |    | 4         |
| 1159 | Histone Deacetylase Inhibitors and Diabetic Kidney Disease. <b>2018</b> , 19,  |    | 38        |

|      |   |     |
|------|---|-----|
| 1158 | The association between cigarette smoking and diabetic nephropathy in Chinese male patients. <b>2018</b> , 55, 1131-1141  | 4   |
| 1157 | Safety and effectiveness of low-protein diet supplemented with ketoacids in diabetic patients with chronic kidney disease. <b>2018</b> , 19, 110  | 14  |
| 1156 | ISPAD Clinical Practice Consensus Guidelines 2018: The delivery of ambulatory diabetes care to children and adolescents with diabetes. <b>2018</b> , 19 Suppl 27, 84-104                            | 55  |
| 1155 | Effects of uric acid on kidney function decline differ depending on baseline kidney function in type 2 diabetic patients. <b>2019</b> , 34, 1328-1335   | 8   |
| 1154 | AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions. <b>2018</b> , 833, 158-164  | 112 |
| 1153 | Evidence of altered brain network centrality in patients with diabetic nephropathy and retinopathy: an fMRI study using a voxel-wise degree centrality approach. <b>2019</b> , 10, 2042018819865723 | 12  |
| 1152 | Hydrogen Sulfide: Recent Progression and Perspectives for the Treatment of Diabetic Nephropathy. <b>2019</b> , 24,  | 46  |
| 1151 | Microparticles as Potential Mediators of High Glucose-Induced Renal Cell Injury. <b>2019</b> , 9,   | 9   |
| 1150 | What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?. <b>2019</b> , 10, 1719-1731   | 3   |
| 1149 | Nanoarchitected peroxidase-mimetic nanozymes: mesoporous nanocrystalline Boron oxide?. <b>2019</b> , 7, 5412-5422   | 37  |
| 1148 | The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases. <b>2019</b> , 17, 264                                  | 35  |
| 1147 | Artificial intelligence predicts the progression of diabetic kidney disease using big data machine learning. <b>2019</b> , 9, 11862   | 51  |
| 1146 | Why Do Patients With Well-Controlled Vascular Risk Factors Develop Progressive Chronic Kidney Disease?. <b>2019</b> , 35, 1170-1180   | 3   |
| 1145 | The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy. <b>2019</b> , 17, 236  | 37  |
| 1144 | Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. <b>2019</b> , 21, 2422-2428   | 23  |
| 1143 | Glucometabolic characteristics and higher vascular complication risk in Korean patients with type 2 diabetes with non-albumin proteinuria. <b>2019</b> , 33, 585-591                                | 2   |
| 1142 | Renal Disease in Diabetes. <b>2019</b> , 791-807  |     |
| 1141 | Chronic kidney disease in patients with obstructive sleep apnea. A narrative review. <b>2019</b> , 47, 74-89  | 15  |

|      |  |     |     |
|------|--|-----|-----|
| 1140 | Basic Research in Diabetic Nephropathy Health Care: A study of the Renoprotective Mechanism of Metformin. <b>2019</b> , 43, 266  |     | 6   |
| 1139 | Comparing the Effect of Dipeptidyl-Peptidase 4 Inhibitors and Sulfonylureas on Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Prospective Open-Label Study. <b>2019</b> , 8, |     | 2   |
| 1138 | Diabetic kidney diseases revisited: A new perspective for a new era. <b>2019</b> , 30, 250-263   |     | 54  |
| 1137 | Xiaokeeping Mixture Attenuates Diabetic Kidney Disease by Modulating TGF-/Smad Pathway in db/db Mice. <b>2019</b> , 2019, 9241896  |     |     |
| 1136 | Notch Signaling in Kidney Development, Maintenance, and Disease. <b>2019</b> , 9,  |     | 19  |
| 1135 | Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. <b>2019</b> , 191, E1128-E1135   |     | 13  |
| 1134 | How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 1667-1669                                      | 6.9 | 8   |
| 1133 | A Validation Study on eGFR Equations in Chinese Patients With Diabetic or Non-diabetic CKD. <b>2019</b> , 10, 581  |     | 5   |
| 1132 | Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care. <b>2019</b> , 13, 485-494                       |     | 3   |
| 1131 | Comment on: Metabolic surgery improves renal injury independent of weight loss: a meta-analysis. <b>2019</b> , 15, 1020-1023   |     | 7   |
| 1130 | SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <b>2019</b> , 7, 845-854  |     | 335 |
| 1129 | From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. <b>2019</b> , 55,   |     | 66  |
| 1128 | microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney. <b>2019</b> , 10, 904                                    |     | 52  |
| 1127 | Association of urinary acidification function with the progression of diabetic kidney disease in patients with type 2 diabetes. <b>2019</b> , 33, 107419   |     | 3   |
| 1126 | FcgRIII Deficiency and FcgRIIb Deficiency Promote Renal Injury in Diabetic Mice. <b>2019</b> , 2019, 3514574   |     | 0   |
| 1125 | Empagliflozin Protects HK-2 Cells from High Glucose-Mediated Injuries via a Mitochondrial Mechanism. <b>2019</b> , 8,  |     | 18  |
| 1124 | Culinary Medicine: Advancing a Framework for Healthier Eating to Improve Chronic Disease Management and Prevention. <b>2019</b> , 41, 2184-2198  |     | 6   |
| 1123 | Progression of diabetic kidney disease in T2DN rats. <b>2019</b> , 317, F1450-F1461  |     | 16  |

|      |   |     |
|------|---|-----|
| 1122 | Association between gain in adiposity and diabetic kidney disease worsening in type 2 diabetes is mediated by deteriorating glycaemic control: A 3-year follow-up analysis. <b>2019</b> , 157, 107812   | 2   |
| 1121 | Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats. <b>2019</b> , 42, 1707-1712   | 1   |
| 1120 | Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". <b>2019</b> , 29, 1127-1150 | 38  |
| 1119 | Transforming growth factor $\alpha$ (TGF $\alpha$ ) and related molecules in chronic kidney disease (CKD). <b>2019</b> , 133, 287-313   | 30  |
| 1118 | Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. <b>2019</b> , 21, 1237-1250  | 114 |
| 1117 | Lysophosphatidic Acid Signaling in Diabetic Nephropathy. <b>2019</b> , 20,  | 24  |
| 1116 | Hyperglycemia induces NF- $\kappa$ B activation and MCP-1 expression via downregulating GLP-1R expression in rat mesangial cells: inhibition by metformin. <b>2019</b> , 43, 940-953  | 14  |
| 1115 | Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. <b>2019</b> , 2, e00072  | 1   |
| 1114 | Effect of Bilastine on Diabetic Nephropathy in DBA2/J Mice. <b>2019</b> , 20,   | 1   |
| 1113 | Mitochondrial Activity and Skeletal Muscle Insulin Resistance in Kidney Disease. <b>2019</b> , 20,  | 14  |
| 1112 | Role of TRPC6 in Progression of Diabetic Kidney Disease. <b>2019</b> , 21, 48   | 23  |
| 1111 | The Alcohol Extract of Nutt Ameliorates Diabetes and Diabetic Nephropathy in db/db Mice through miR-192/miR-200b and PTEN/AKT and ZEB2/ECM Pathways. <b>2019</b> , 2019, 5280514  | 8   |
| 1110 | The Level of Serum Albumin Is Associated with Renal Prognosis in Patients with Diabetic Nephropathy. <b>2019</b> , 2019, 7825804  | 26  |
| 1109 | Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. <b>2019</b> , 18, 33  | 20  |
| 1108 | Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. <b>2019</b> , 15, 327-345  | 128 |
| 1107 | Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy. <b>2019</b> , 95, 1418-1432   | 42  |
| 1106 | The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat. <b>2019</b> , 18, 40   | 22  |
| 1105 | The Other Glucose Transporter, SGLT1 - Also a Potential Trouble Maker in Diabetes?. <b>2019</b> , 30, 519-521   | 2   |

|      |   |    |
|------|---|----|
| 1104 | Galectin-3 as a prognostic biomarker for diabetic nephropathy. <b>2019</b> , 12, 325-331  | 8  |
| 1103 | Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept. <b>2019</b> , 60, 1325-1332  | 7  |
| 1102 | . <b>2019</b> ,   | 0  |
| 1101 | Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <b>2019</b> , 30, 2229-2242                              | 57 |
| 1100 | ANGPTL4: A Predictive Marker for Diabetic Nephropathy. <b>2019</b> , 2019, 4943191  | 12 |
| 1099 | Human mesenchymal stromal cells broadly modulate high glucose-induced inflammatory responses of renal proximal tubular cell monolayers. <b>2019</b> , 10, 329                               | 3  |
| 1098 | Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry. <b>2019</b> , 2, e1918169                          | 49 |
| 1097 | Nonproteinuric progressive diabetic kidney disease. <b>2019</b> , 28, 227-232   | 9  |
| 1096 | Cigarette smoke inhalation aggravates diabetic kidney injury in rats. <b>2019</b> , 8, 964-971  | 2  |
| 1095 | Protective effect of vanillin on diabetic nephropathy by decreasing advanced glycation end products in rats. <b>2019</b> , 239, 117088  | 11 |
| 1094 | Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. <b>2019</b> , 20,                       | 25 |
| 1093 | Chinese Herbal Medicine in Ameliorating Diabetic Kidney Disease via Activating Autophagy. <b>2019</b> , 2019, 9030893   | 4  |
| 1092 | The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy. <b>2019</b> , 14, 78-83   | 5  |
| 1091 | Implications of a Family History of Diabetes and Rapid eGFR Decline in Patients With Type 2 Diabetes and Biopsy-Proven Diabetic Kidney Disease. <b>2019</b> , 10, 855                       | 6  |
| 1090 | Impact of sex on diabetic nephropathy and the renal transcriptome in UNx db/db C57BLKS mice. <b>2019</b> , 7, e14333  | 5  |
| 1089 | hs-CRP Is Associated With Incident Diabetic Nephropathy: Findings From the Jackson Heart Study. <b>2019</b> , 42, 2083-2089   | 17 |
| 1088 | Refining the Mouse Subtotal Nephrectomy in Male 129S2/SV Mice for Consistent Modeling of Progressive Kidney Disease With Renal Inflammation and Cardiac Dysfunction. <b>2019</b> , 10, 1365 | 5  |
| 1087 | Tocilizumab prevents renal function of a patient with diabetic kidney disease: case report. <b>2019</b> , 3, 53-56  |    |

|      |  |       |
|------|--|-------|
| 1086 | Treatment Goals in Diabetic Nephropathy. <b>2019</b> , 435-450   | 0     |
| 1085 | Preventing and treating kidney disease in patients with type 2 diabetes. <b>2019</b> , 20, 277-294   | 23    |
| 1084 | Diabetic Kidney Disease. <b>2019</b> , 42-61.e5  |       |
| 1083 | Effects of neutrophil-lymphocyte ratio on renal function and histologic lesions in patients with diabetic nephropathy. <b>2019</b> , 24, 1115-1121   | 5     |
| 1082 | Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. <b>2019</b> , 45, 110-121   | 31    |
| 1081 | The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <b>2019</b> , 21, 575-583  | 9     |
| 1080 | Association between nonalbumin proteinuria and renal tubular damage of N-acetyl-D-glucosaminidase and its clinical relevance in patients with type 2 diabetes without albuminuria. <b>2019</b> , 33, 255-260   | 6     |
| 1079 | Low-intensity shockwave therapy in the treatment of diabetic nephropathy: a prospective Phase 1 study. <b>2020</b> , 35, 1385-1392   | 4     |
| 1078 | Synergistic interaction of hypertension and diabetes on chronic kidney disease: Insights from the National Health and Nutrition Examination Survey 1999-2006. <b>2020</b> , 34, 107447   | 1     |
| 1077 | Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". <b>2020</b> , 33, 9-35 | 38    |
| 1076 | Design and validation of a scoring model for differential diagnosis of diabetic nephropathy and nondiabetic renal diseases in type 2 diabetic patients. <b>2020</b> , 12, 237-246  | 1     |
| 1075 | Preserving Kidney Function Instead of Replacing It. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 129-131   | 6.9 4 |
| 1074 | Differences in proximal tubular solute clearance across common etiologies of chronic kidney disease. <b>2020</b> , 35, 1916-1923   | 4     |
| 1073 | BRAIN FUNCTION ALTERATIONS IN PATIENTS WITH DIABETIC NEPHROPATHY COMPLICATED BY RETINOPATHY UNDER RESTING STATE CONDITIONS ASSESSED BY VOXEL-MIRRORED HOMOTOPIC CONNECTIVITY. <b>2020</b> , 26, 291-298  | 4     |
| 1072 | Primary Care Providers' Acceptance of Pharmacists' Recommendations to Support Optimal Medication Management for Patients with Diabetic Kidney Disease. <b>2020</b> , 35, 63-69   | 3     |
| 1071 | Depression-like behavior, hyperglycemia, oxidative stress, and neuroinflammation presented in diabetic mice are reversed by the administration of 1-methyl-3-(phenylselanyl)-1H-indole. <b>2020</b> , 120, 91-102  | 14    |
| 1070 | The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. <b>2020</b> , 41,  | 29    |
| 1069 | Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials. <b>2020</b> , 11, 369-386  | 35    |

|      |  |    |
|------|--|----|
| 1068 | Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition. <b>2020</b> , 68, 109506 | 32 |
| 1067 | Interactions Between Diet Quality and Interleukin-6 Genotypes Are Associated With Metabolic and Renal Function Parameters in Mexican Patients With Type 2 Diabetes Mellitus. <b>2020</b> , 30, 223-231   | 1  |
| 1066 | Novel Biomarkers for Change in Renal Function in People With Dysglycemia. <b>2020</b> , 43, 433-439  | 1  |
| 1065 | Decreased microcirculatory function measured by perfusion index is a novel indicator of diabetic kidney disease in patients with type 2 diabetes. <b>2020</b> , 11, 681-687  | 2  |
| 1064 | Reversal of secondary complications of type 1 diabetes (nephropathy, neuropathy, retinopathy, and cardiopathy). <b>2020</b> , 279-293  |    |
| 1063 | Machine Learning Approaches Reveal Metabolic Signatures of Incident Chronic Kidney Disease in Individuals With Prediabetes and Type 2 Diabetes. <b>2020</b> , 69, 2756-2765  | 5  |
| 1062 | Sex Differences in Diabetes- and TGF- $\beta$ -Induced Renal Damage. <b>2020</b> , 9,  | 10 |
| 1061 | Collecting duct cells show differential retinoic acid responses to acute versus chronic kidney injury stimuli. <b>2020</b> , 10, 16683   | 0  |
| 1060 | Anhuienoside C Attenuates Podocyte Injury in Diabetic Nephropathy Rats. <b>2020</b> , 18, 1559325820939010   | 1  |
| 1059 | Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?. <b>2020</b> , 8, 870-871   | 2  |
| 1058 | Deep Neural Network for Predicting Diabetic Retinopathy from Risk Factors. <b>2020</b> , 8, 1620   | 9  |
| 1057 | Combinational Use of Antiplatelet Medication Sarpogrelate with Therapeutic Drug Rosuvastatin in Treating High-Cholesterol Diet-Induced Chronic Kidney Disease in ApoE-Deficient Mice. <b>2020</b> , 2020, 1809326  | 1  |
| 1056 | The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. <b>2020</b> , 170, 108462   | 5  |
| 1055 | Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!. <b>2021</b> , 179, 31-71   | 2  |
| 1054 | Thyroid Hormone Signalling Alteration in Diabetic Nephropathy and Cardiomyopathy: a "Switch" to the Foetal Gene Programme. <b>2020</b> , 20, 58  | 2  |
| 1053 | Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement. <b>2020</b> , 11, 2791-2827   | 9  |
| 1052 | AGE/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy. <b>2020</b> , 131, 110655   | 13 |
| 1051 | Mitochondrial pyruvate carrier: a potential target for diabetic nephropathy. <b>2020</b> , 21, 274   | 2  |



|      |   |        |
|------|---|--------|
| 1050 | Polyphenolic compounds of amla prevent oxidative stress and fibrosis in the kidney and heart of 2K1C rats. <b>2020</b> , 8, 3578-3589   | 8      |
| 1049 | Pattern recognition receptor-mediated inflammation in diabetic vascular complications. <b>2020</b> , 40, 2466-2484  | 18     |
| 1048 | Effects of Allicin on Pathophysiological Mechanisms during the Progression of Nephropathy Associated to Diabetes. <b>2020</b> , 9,  | 8      |
| 1047 | Intra-individual variability of eGFR trajectories in early diabetic kidney disease and lack of performance of prognostic biomarkers. <b>2020</b> , 10, 19743  | 3      |
| 1046 | Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease: A Review of the Studies Using Syngeneic, Autologous, Allogeneic, and Xenogeneic Cells. <b>2020</b> , 2020, 8833725   | 5      |
| 1045 | Exosomal circ_DLGAP4 promotes diabetic kidney disease progression by sponging miR-143 and targeting ERBB3/NF- $\kappa$ B/MMP-2 axis. <b>2020</b> , 11, 1008   | 18     |
| 1044 | Higher Serum Asprosin Level is Associated with Urinary Albumin Excretion and Renal Function in Type 2 Diabetes. <b>2020</b> , 13, 4341-4351   | 6      |
| 1043 | Survival and analysis of predictors of mortality in patients undergoing replacement renal therapy: a 20-year cohort. <b>2020</b> , 21, 502  | 5      |
| 1042 | Indications for renal biopsy in patients with diabetes. Joint position statement of the Italian Society of Nephrology and the Italian Diabetes Society. <b>2020</b> , 30, 2123-2132   | 1      |
| 1041 | Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 1715-1727 | 6.9 28 |
| 1040 | MicroRNA, Diabetes Mellitus and Colorectal Cancer. <b>2020</b> , 8,   | 5      |
| 1039 | LncRNA MIR503HG Promotes High-Glucose-Induced Proximal Tubular Cell Apoptosis by Targeting miR-503-5p/Bcl-2 Pathway. <b>2020</b> , 13, 4507-4517  | 7      |
| 1038 | Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM). <b>2020</b> , 12,   | 34     |
| 1037 | Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <b>2020</b> ,  | 20     |
| 1036 | Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients. <b>2020</b> , 42, 1111-11174  |        |
| 1035 | Elabela levels in patients with type 2 diabetes: can it be a marker for diabetic nephropathy?. <b>2020</b> , 20, 833-840  | 3      |
| 1034 | Therapeutic Efficacy of Piperazine Ferulate Combined With Irbesartan in Diabetic Nephropathy: A Systematic Review and Meta-analysis. <b>2020</b> , 42, 2196-2212  | 5      |
| 1033 | Extracellular vesicles carrying miRNAs in kidney diseases: a systemic review. <b>2020</b> , 24, 1103-1121   | 3      |

|      |  |    |
|------|--|----|
| 1032 | Integrative Omics Analyses Reveal Epigenetic Memory in Diabetic Renal Cells Regulating Genes Associated With Kidney Dysfunction. <b>2020</b> , 69, 2490-2502   | 4  |
| 1031 | SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TYPE 1 LEVELS EXHIBIT THE BETTER ASSOCIATION WITH RENAL OUTCOMES THAN TRADITIONAL RISK FACTORS IN CHINESE SUBJECTS WITH TYPE 2 DIABETES MELLITUS. <b>2020</b> , | 2  |
| 1030 | Mechanisms of Herbal Nephroprotection in diabetes mellitus. <b>2020</b> , 2020, 5710513  | 11 |
| 1029 | Identification of metabolic markers in patients with type 2 Diabetes by Ultrafast gas chromatography coupled to electronic nose. A pilot study. <b>2020</b> , 34, e4956                                | 6  |
| 1028 | Biomarkers in diabetic kidney disease. <b>2020</b> , 185-208   |    |
| 1027 | Autophagy in kidney homeostasis and disease. <b>2020</b> , 16, 489-508   | 77 |
| 1026 | Relationship between pulmonary function and albuminuria in type 2 diabetic patients with preserved renal function. <b>2020</b> , 20, 112   | 1  |
| 1025 | Butyrate alleviates diabetic kidney disease by mediating the miR-7a-5p/P311/TGF- $\beta$ pathway. <b>2020</b> , 34, 10462-10475  | 7  |
| 1024 | Mitochondrial DNA: A New Predictor of Diabetic Kidney Disease. <b>2020</b> , 2020, 3650937   | 4  |
| 1023 | Polysaccharides from <i>Armillariella tabescens</i> mycelia ameliorate renal damage in type 2 diabetic mice. <b>2020</b> , 162, 1682-1691  | 10 |
| 1022 | Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. <b>2020</b> , 11, 336                          | 44 |
| 1021 | The future of Diabetic Kidney Disease management: reducing the unmet need. <b>2020</b> , 33, 1163-1169   | 3  |
| 1020 | The potential roles of chitosan oligosaccharide in prevention of kidney injury in obese and diabetic conditions. <b>2020</b> , 11, 7371-7388   | 8  |
| 1019 | Mechanisms and Functions of Mitophagy and Potential Roles in Renal Disease. <b>2020</b> , 11, 935  | 8  |
| 1018 | Effects of gastric bypass surgery on expression of glucose transporters and fibrotic biomarkers in kidney of diabetic fatty rats. <b>2020</b> , 16, 1242-1248  | 4  |
| 1017 | Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results. <b>2020</b> , 11, 1983-1999  | 6  |
| 1016 | Blood glucose prediction model for type 1 diabetes based on artificial neural network with time-domain features. <b>2020</b> , 40, 1586-1599   | 13 |
| 1015 | Renal protection with glucagon-like peptide-1 receptor agonists. <b>2020</b> , 54, 91-101  | 9  |

|      |  |    |
|------|--|----|
| 1014 | Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes. <b>2020</b> , 115, 102543  | 8  |
| 1013 | Prevalence of Vascular Complications Among Type 2 Diabetic Patients in a Rural Health Center in South India. <b>2020</b> , 11, 2150132720959962  | 1  |
| 1012 | Obesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a cross-sectional study in a tertiary nephrology centre. <b>2020</b> , 10, e12402            | 10 |
| 1011 | The gut microbiome in differential diagnosis of diabetic kidney disease and membranous nephropathy. <b>2020</b> , 42, 1100-1110  | 6  |
| 1010 | SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients. <b>2020</b> , 13, 281-296  | 10 |
| 1009 | Association of Glomerular Complement C4c Deposition With the Progression of Diabetic Kidney Disease in Patients With Type 2 Diabetes. <b>2020</b> , 11, 2073   | 3  |
| 1008 | Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences. <b>2020</b> , 29, 523-530  | 0  |
| 1007 | Biomarkers of Inflammation and Glomerular Filtration Rate in Individuals with Recent-Onset Type 1 and Type 2 Diabetes. <b>2020</b> , 105,  | 4  |
| 1006 | Methylation pattern of urinary DNA as a marker of kidney function decline in diabetes. <b>2020</b> , 8,  | 5  |
| 1005 | Parallel assessment of albuminuria and plasma sTNFR1 in people with type 2 diabetes and advanced chronic kidney disease provides accurate prognostication of the risks of renal decline and death. <b>2020</b> , 10, 14852 | 3  |
| 1004 | Mitochondria-Associated Endoplasmic Reticulum Membranes (MAMs) and Their Prospective Roles in Kidney Disease. <b>2020</b> , 2020, 3120539  | 11 |
| 1003 | Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments. <b>2020</b> , 11, 568  | 25 |
| 1002 | Impaired renal hemodynamics and glomerular hyperfiltration contribute to hypertension-induced renal injury. <b>2020</b> , 319, F624-F635   | 4  |
| 1001 | Acute pyelonephritis in children and the risk of end-stage kidney disease. <b>2021</b> , 34, 1757-1765   | 0  |
| 1000 | Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model. <b>2020</b> , 10, 14659   | 20 |
| 999  | Impact of Liver Cirrhosis on Incidence of Dialysis Among Patients with Type 2 Diabetes. <b>2020</b> , 11, 2611-2628  | 1  |
| 998  | SGLT2-Inhibitoren kein Meilenstein in der Therapie des Typ-2-Diabetes. <b>2020</b> , 15, 368-371   |    |
| 997  | Novel therapeutic agents for the treatment of diabetic kidney disease. <b>2020</b> , 29, 1277-1293   | 3  |

|     |  |    |
|-----|--|----|
| 996 | Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?. <b>2020</b> , 11, 289               | 20 |
| 995 | The protective effect of green tea on diabetes-induced hepato-renal pathological changes: a histological and biochemical study. <b>2020</b> , 1-12   | 2  |
| 994 | Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). <b>2020</b> , 17, 1479164120970933                      | 1  |
| 993 | Bu-Shen-Huo-Xue Decoction Ameliorates Diabetic Nephropathy by Inhibiting Rac1/PAK1/p38MAPK Signaling Pathway in High-Fat Diet/Streptozotocin-Induced Diabetic Mice. <b>2020</b> , 11, 587663 | 5  |
| 992 | Ellagic Acid as a Tool to Limit the Diabetes Burden: Updated Evidence. <b>2020</b> , 9,  | 11 |
| 991 | The Therapeutic Effect of Active Vitamin D Supplementation in Preventing the Progression of Diabetic Nephropathy in a Diabetic Mouse Model. <b>2020</b> , 2020, 7907605                      | 6  |
| 990 | Micronucleus frequency in chronic kidney disease patients: A review. <b>2020</b> , 786, 108340   | 4  |
| 989 | Prevalence and associations of moderately increased albuminuria in patients with type 2 diabetes in United Arab Emirates. <b>2020</b> , 14, 1865-1870  | 0  |
| 988 | Effects of Hyperuricemia on Beta-Cell Function, Renal Function, and Lipid Panels of Patients with Diabetic Kidney Disease: A Gender-Based Retrospective Study. <b>2020</b> , 26, 103-111     | 1  |
| 987 | Pyruvate-Enriched Oral Rehydration Solution Improves Glucometabolic Disorders in the Kidneys of Diabetic Mice. <b>2020</b> , 2020, 2817972   | 2  |
| 986 | A Mutation in -Adducin Impairs Autoregulation of Renal Blood Flow and Promotes the Development of Kidney Disease. <b>2020</b> , 31, 687-700  | 11 |
| 985 | Characteristic Renal Histology of a 81-Year-Old Patient with a 30-Year History of Diabetes Mellitus: A Case Report. <b>2020</b> , 9, 338-343   | 1  |
| 984 | [Diabetes and lipids - lipids and diabetes]. <b>2020</b> , 162, 38-42  |    |
| 983 | Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. <b>2020</b> , 313, 76-82                            | 9  |
| 982 | Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A. <b>2020</b> , 31, 1267-1281         | 53 |
| 981 | Neutrophil-to-lymphocyte ratio is a predictor of renal dysfunction in Japanese patients with type 2 diabetes. <b>2020</b> , 14, 481-487  | 1  |
| 980 | Loss of NF-E2 expression contributes to the induction of profibrotic signaling in diabetic kidneys. <b>2020</b> , 254, 117783  | 4  |
| 979 | Sex Differences in Obesity-Induced Inflammation. <b>2020</b> ,   | 2  |

|     |  |    |
|-----|--|----|
| 978 | The Role of Chemokines and Chemokine Receptors in Diabetic Nephropathy. <b>2020</b> , 21,  | 9  |
| 977 | Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure. <b>2020</b> , 31, 1594-1601                 | 9  |
| 976 | Diabetic Kidney Disease: It Don't Get No Respect. <b>2020</b> , 38, 124-125  |    |
| 975 | Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review. <b>2020</b> , 11, 1237-1250   | 3  |
| 974 | Inhibition of interleukin-6 on matrix protein production by glomerular mesangial cells and the pathway involved. <b>2020</b> , 318, F1478-F1488  | 8  |
| 973 | The Interplay of Renin-Angiotensin System and Toll-Like Receptor 4 in the Inflammation of Diabetic Nephropathy. <b>2020</b> , 2020, 6193407  | 18 |
| 972 | Salidroside protects against diabetes mellitus-induced kidney injury and renal fibrosis by attenuating TGF- $\beta$ 1 and Wnt1/3a/Eatenin signalling. <b>2020</b> , 47, 1692-1704            | 3  |
| 971 | Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy. <b>2020</b> , 21,   | 43 |
| 970 | Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents. <b>2020</b> , 74, e13586   | 0  |
| 969 | Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients. <b>2020</b> , 8, 339   | 5  |
| 968 | The early effects of uninephrectomy on rat kidney metabolic state using optical imaging. <b>2020</b> , 13, e202000089  |    |
| 967 | Targeting NF- $\kappa$ B by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy. <b>2020</b> , 21, | 5  |
| 966 | Interstitial eosinophilic infiltration in diabetic nephropathy is indicative of poor prognosis, with no therapy benefit from steroid. <b>2020</b> , 12, 881-894                              | 4  |
| 965 | Relationship between trajectory of sleep quality and short-term changes in residual renal function in stage 3-5 chronic kidney disease patients. <b>2020</b> , 24, 557-564                   |    |
| 964 | The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes. <b>2020</b> , 11, 835-844  | 14 |
| 963 | Pyruvate alleviates high glucose-induced endoplasmic reticulum stress and apoptosis in HK-2 cells. <b>2020</b> , 10, 827-834   | 7  |
| 962 | Exploring the role of the metabolite-sensing receptor GPR109a in diabetic nephropathy. <b>2020</b> , 318, F835-F842  | 3  |
| 961 | The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review. <b>2020</b> , 15, e0230512                                     | 36 |

|     |   |    |
|-----|---|----|
| 960 | Uric acid and inflammation in kidney disease. <b>2020</b> , 318, F1327-F1340  | 22 |
| 959 | Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients. <b>2020</b> , 9,  | 3  |
| 958 | Use of urinary proteomics in diagnosis and monitoring of diabetic kidney disease. <b>2020</b> , 8, 261-262  | 4  |
| 957 | Geschlechtsunterschiede bei der diabetischen Nephropathie. <b>2020</b> , 15, 136-144  |    |
| 956 | Novel Assessment of Urinary Albumin Excretion in Type 2 Diabetes Patients by Raman Spectroscopy. <b>2020</b> , 10,  | 9  |
| 955 | Importance of Identifying Novel Biomarkers of Microvascular Damage in Type 1 Diabetes. <b>2020</b> , 24, 507-515  | 3  |
| 954 | MiR-325-3p inhibits renal inflammation and fibrosis by targeting CCL19 in diabetic nephropathy. <b>2020</b> , 47, 1850-1860   | 16 |
| 953 | Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol. <b>2020</b> , 21, 242  | 4  |
| 952 | Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trial. <b>2020</b> , 12, 929-941 | 0  |
| 951 | Factors Associated with Risk of Diabetic Complications in Novel Cluster-Based Diabetes Subgroups: A Japanese Retrospective Cohort Study. <b>2020</b> , 9,   | 17 |
| 950 | Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. <b>2020</b> , 98, 839-848  | 65 |
| 949 | MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease. <b>2020</b> , 63, 1916-1931   | 9  |
| 948 | Reduction in Serum High-Sensitivity C-Reactive Protein Favors Kidney Outcomes in Patients with Impaired Fasting Glucose or Diabetes. <b>2020</b> , 2020, 2720905  | 1  |
| 947 | Burden of Undiagnosed Type 2 Diabetes in Diabetic Kidney Disease: A Japanese Retrospective Cohort Study. <b>2020</b> , 9,   | 0  |
| 946 | Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes. <b>2020</b> , 3, e00129  | 3  |
| 945 | Association of diabetic nephropathy with the severity of obstructive sleep apnea-hypopnea syndrome in patients with type 2 diabetes mellitus. <b>2020</b> , 67, 515-522   | 2  |
| 944 | Implications of immunoglobulin G deposit in glomeruli in Chinese patients with diabetic nephropathy. <b>2020</b> , 12, 521-531  | 2  |
| 943 | Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice. <b>2020</b> , 8, e14364   | 6  |

|     |   |     |
|-----|---|-----|
| 942 | ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway. <b>2019</b> , 10, 1596  | 7   |
| 941 | The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons. <b>2020</b> , 98, 323-342  | 22  |
| 940 | Diabetes mellitus, insuficiencia cardiaca y enfermedad renal crónica. <b>2020</b> , 27, 3-6   | 0   |
| 939 | Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets. <b>2020</b> , 98, 116-132   | 9   |
| 938 | Extract Ameliorated Renal Inflammation by Regulation of NLRP3 Inflammasome-Associated Hyperinflammation in Type 2 Diabetic Mice. <b>2020</b> , 9,   | 4   |
| 937 | Porcine models for studying complications and organ crosstalk in diabetes mellitus. <b>2020</b> , 380, 341-378  | 28  |
| 936 | preparations as adjuvant therapy for diabetic kidney disease: a systematic review and meta-analysis. <b>2020</b> , 58, 138-145  | 6   |
| 935 | Aucubin alleviates diabetic nephropathy by inhibiting NF- $\kappa$ B activation and inducing SIRT1/SIRT3-FOXO3a signaling pathway in high-fat diet/streptozotocin-induced diabetic mice. <b>2020</b> , 64, 103702 | 13  |
| 934 | Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. <b>2020</b> , 75, 422-434   | 120 |
| 933 | Association of Prediabetes With CKD Progression and Adverse Cardiovascular Outcomes: An Analysis of the CRIC Study. <b>2020</b> , 105,  | 8   |
| 932 | Cell junction proteins: Crossing the glomerular filtration barrier in diabetic nephropathy. <b>2020</b> , 148, 475-482  | 17  |
| 931 | High-protein diet accelerates diabetes and kidney disease in the BTBR mouse. <b>2020</b> , 318, F763-F771   | 8   |
| 930 | Role of Transient Receptor Potential Canonical Channel 6 (TRPC6) in Diabetic Kidney Disease by Regulating Podocyte Actin Cytoskeleton Rearrangement. <b>2020</b> , 2020, 6897390                                  | 13  |
| 929 | Mechanisms of Synergistic Interactions of Diabetes and Hypertension in Chronic Kidney Disease: Role of Mitochondrial Dysfunction and ER Stress. <b>2020</b> , 22, 15  | 12  |
| 928 | Is the type of diabetes treatment relevant to outcome of COVID-19?. <b>2020</b> , 12, 486-487   | 3   |
| 927 | Zinc- $\alpha$ -glycoprotein is associated with non-albuminuric chronic kidney disease progression in type 2 diabetes: a retrospective study with 4-year follow-up. <b>2020</b> , 37, 1919-1926                   | 0   |
| 926 | Peripheral perfusion, measured by perfusion index, is a novel indicator for renal events in patients with type 2 diabetes mellitus. <b>2020</b> , 10, 6054  |     |
| 925 | Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. <b>2020</b> , 22 Suppl 1, 32-45  | 19  |

|     |   |     |    |
|-----|---|-----|----|
| 924 | Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. <b>2020</b> , 22 Suppl 1, 46-54                         |     | 17 |
| 923 | Injectable Silk Fibroin-Based Hydrogel for Sustained Insulin Delivery in Diabetic Rats.. <b>2020</b> , 3, 3544-3552   |     | 11 |
| 922 | Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities. <b>2020</b> , 21,  |     | 52 |
| 921 | Editorial: Genetics of Kidney Diseases. <b>2020</b> , 11, 305   |     | 1  |
| 920 | Association between reduced kidney function and incident hypoglycaemia in people with diabetes: The Stockholm Creatinine Measurements (SCREAM) project. <b>2020</b> , 22, 1425-1435   |     | 2  |
| 919 | 20(S)-Ginsenoside Rg3 Protects Kidney from Diabetic Kidney Disease via Renal Inflammation Depression in Diabetic Rats. <b>2020</b> , 2020, 7152176  |     | 5  |
| 918 | Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 285-288  | 6.9 | 13 |
| 917 | Transforming Growth Factor-Beta1 in Diabetic Kidney Disease. <b>2020</b> , 8, 187   |     | 37 |
| 916 | Kynurenine/Tryptophan Ratio Predicts Angiotensin Receptor Blocker Responsiveness in Patients with Diabetic Kidney Disease. <b>2020</b> , 10,  |     | 4  |
| 915 | GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. <b>2020</b> , 9,   |     | 27 |
| 914 | Prevalence and Risk Factors of Chronic Kidney Disease among Type 2 Diabetes Patients: A Cross-Sectional Study in Primary Care Practice. <b>2020</b> , 10, 6205  |     | 26 |
| 913 | Associations between diabetes and sex with peritoneal dialysis technique and patient survival: Results from the Australia and New Zealand Dialysis and Transplant Registry cohort study. <b>2021</b> , 41, 57-68                        |     | 1  |
| 912 | Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. <b>2021</b> , 9, 2-6  |     | 6  |
| 911 | A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. <b>2021</b> , 15, 31-51  |     | 13 |
| 910 | Impact of Diabetes Mellitus on Knee Osteoarthritis Pain and Physical and Mental Status: Data From the Osteoarthritis Initiative. <b>2021</b> , 73, 540-548  |     | 6  |
| 909 | Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations. <b>2021</b> , 23, 299-317   |     | 2  |
| 908 | Antihyperglycaemic activity of ethylacetate extract of <i>Chlorophytum alismifolium</i> in type 2 diabetes: The involvement of peroxisome proliferator-activated receptor- $\alpha$ and dipeptidyl peptidase-4. <b>2021</b> , 19, 78-84 |     | 3  |
| 907 | Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017. <b>2021</b> , 12, 346-356  |     | 17 |



|     |  |     |    |
|-----|--|-----|----|
| 906 | Potential Repressive Impact of microRNA-20a on Renal Tubular Damage in Diabetic Kidney Disease by Targeting C-X-C Motif Chemokine Ligand 6. <b>2021</b> , 52, 58-68  |     | 0  |
| 905 | Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. <b>2021</b> , 26, 377-390   |     | 4  |
| 904 | Autophagy blockade mechanistically links proton pump inhibitors to worsened diabetic nephropathy and aborts the renoprotection of metformin/enalapril. <b>2021</b> , 265, 1188-18  |     | 3  |
| 903 | The Novel Phosphate and Bile Acid Sequestrant Polymer SAR442357 Delays Disease Progression in a Rat Model of Diabetic Nephropathy. <b>2021</b> , 376, 190-203  |     | 0  |
| 902 | Synergy between the pay-for-performance scheme and better physician-patient relationship might reduce the risk of retinopathy in patients with type 2 diabetes. <b>2021</b> , 12, 819-827  |     | 1  |
| 901 | Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. <b>2021</b> , 17, 227-244  |     | 28 |
| 900 | SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <b>2021</b> , 77, 94-109  |     | 27 |
| 899 | Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. <b>2021</b> , 77, 481-489   |     | 12 |
| 898 | QiDiTangShen granules modulated the gut microbiome composition and improved bile acid profiles in a mouse model of diabetic nephropathy. <b>2021</b> , 133, 111061   |     | 6  |
| 897 | SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond. <b>2021</b> , 9, 3-5   |     | 0  |
| 896 | A retrospective observational population-based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate 2021, 23, 916-928  |     | 1  |
| 895 | 4-Hydroxy-2-nonenal, a lipid peroxidation product, as a biomarker in diabetes and its complications: challenges and opportunities. <b>2021</b> , 55, 547-561   |     | 2  |
| 894 | Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 16, 59-69 | 6.9 | 7  |
| 893 | Effects of the Dietary Approaches to Stop Hypertension Diet and Sodium Reduction on Blood Pressure in Persons With Diabetes. <b>2021</b> , 77, 265-274   |     | 3  |
| 892 | Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.. <b>2021</b> , 2, 254-262  |     | 1  |
| 891 | Integrating Patient Priorities with Science by Community Engagement in the Kidney Precision Medicine Project. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 660-668                             | 6.9 | 3  |
| 890 | Perfluoroalkyl acids and their isomers, diabetes, anemia, and albuminuria: Variabilities with deteriorating kidney function. <b>2021</b> , 208, 111625   |     | 2  |
| 889 | Pharmacological modulation of the hydrogen sulfide (H <sub>2</sub> S) system by dietary H <sub>2</sub> S-donors: A novel promising strategy in the prevention and treatment of type 2 diabetes mellitus. <b>2021</b> , 35, 1817-1846       |     | 6  |

|     |   |    |
|-----|---|----|
| 888 | SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <b>2021</b> , 70, 1-16                                   | 18 |
| 887 | Non-diabetic glomerular lesions in diabetic kidney disease: clinical predictors and outcome in an Eastern European cohort. <b>2021</b> , 53, 739-747  | 3  |
| 886 | Activation of GPR120 in podocytes ameliorates kidney fibrosis and inflammation in diabetic nephropathy. <b>2021</b> , 42, 252-263   | 8  |
| 885 | The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study. <b>2021</b> , 32, 138-150   | 15 |
| 884 | Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. <b>2021</b> , 26, 337-345   | 12 |
| 883 | Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. <b>2021</b> , 58, 81-91                       | 14 |
| 882 | A Study of Association of Urinary Nephryn with Albuminuria in Patients with Diabetic Nephropathy. <b>2021</b> , 31, 142-148   | 0  |
| 881 | Hydrogen water therapy in histopathological improvement of diabetic nephropathy on streptozotocin-induced diabetic rats. <b>2021</b> ,  |    |
| 880 | Myricitrin, a Glycosyloxyflavone in Bark Ameliorates Diabetic Nephropathy via Improving Glycemic Status, Reducing Oxidative Stress, and Suppressing Inflammation. <b>2021</b> , 26,                           | 6  |
| 879 | Payer budget impact of an artificial intelligence diagnostic to modify diabetic kidney disease progression. <b>2021</b> , 24, 972-982   | 2  |
| 878 | Ezetimibe attenuates experimental diabetes and renal pathologies via targeting the advanced glycation, oxidative stress and AGE-RAGE signalling in rats. <b>2021</b> , 1-16                                   | 3  |
| 877 | Long Noncoding RNAs and Their Therapeutic Promise in Diabetic Nephropathy. <b>2021</b> , 145, 404-414   | 3  |
| 876 | Identification of fibronectin 1 (FN1) and complement component 3 (C3) as immune infiltration-related biomarkers for diabetic nephropathy using integrated bioinformatic analysis. <b>2021</b> , 12, 5386-5401 | 4  |
| 875 | The Effect of Neutrophil Gelatinase-Associated Lipocalin in the Clinical Diagnosis of Diabetic Kidney Disease. <b>2021</b> , 11, 3328-3332  |    |
| 874 | DsbA-L protects against diabetic renal injury through the adipo-renal axis.   |    |
| 873 | Wnt5a promotes renal tubular inflammation in diabetic nephropathy by binding to CD146 through noncanonical Wnt signaling. <b>2021</b> , 12, 92  | 4  |
| 872 | Reference genes for mesangial cell and podocyte qPCR gene expression studies under high-glucose and renin-angiotensin-system blocker conditions.  |    |
| 871 | Correlation between Serum Bone Turnover Markers and Estimated Glomerular Filtration Rate in Chinese Patients with Diabetes. <b>2021</b> , 2021, 6731218   | 1  |

|     |   |    |
|-----|---|----|
| 870 | Diabetes Complications in Racial and Ethnic Minority Populations in the USA. <b>2021</b> , 21, 2  | 13 |
| 869 | Optimal Early Diagnosis and Monitoring of Diabetic Kidney Disease in Type 2 Diabetes Mellitus: Addressing the Barriers to Albuminuria Testing. <b>2021</b> , 12, 21501327211003683                  | 5  |
| 868 | Rotten to the Cortex: Ceramide-Mediated Lipotoxicity in Diabetic Kidney Disease. <b>2020</b> , 11, 622692   | 4  |
| 867 | The Elderly Kidney. <b>2021</b> , 135-145   |    |
| 866 | Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <b>2021</b> , 14, 226-236 | 1  |
| 865 | Preexistent chronic disorders, often directly affecting pregnancy. <b>2021</b> , 99-174   |    |
| 864 | Icariin ameliorates streptozocin-induced diabetic nephropathy through suppressing the TLR4/NF- $\kappa$ B signal pathway. <b>2021</b> , 12, 1241-1251   | 8  |
| 863 | TrammelGraph: visual graph abstraction for comparison. <b>2021</b> , 24, 365-379  | 4  |
| 862 | Telemedicine maybe an effective solution for management of chronic disease during the COVID-19 epidemic. <b>2021</b> , 22, e48  | 9  |
| 861 | Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF- $\kappa$ B/miR-155-5p inflammatory loop. <b>2021</b> , 12, 19-46                                      | 12 |
| 860 | Diabetes, the kidney and the heart-A tale of metabolic mayhem. <b>2021</b> , 14, 9-11   |    |
| 859 | Heterogeneity in renal end-points of cardiovascular outcomes trials in Type 2 diabetes. <b>2021</b> , 10, 169-173   | 1  |
| 858 | Risk factors of adverse outcome of COVID-19 and experience of Tocilizumab administration in patients on maintenance hemodialysis due to diabetic kidney disease. <b>2021</b> , 24, 17-31            |    |
| 857 | NQO1 Deficiency Aggravates Renal Injury by Dysregulating Vps34/ATG14L Complex during Autophagy Initiation in Diabetic Nephropathy. <b>2021</b> , 10,  | 1  |
| 856 | Therapeutic Potential of Mesenchymal Stem Cells in a Pre-Clinical Model of Diabetic Kidney Disease and Obesity. <b>2021</b> , 22,   | 7  |
| 855 | Based on Network Pharmacology Tools to Investigate the Molecular Mechanism of Cordyceps sinensis on the Treatment of Diabetic Nephropathy. <b>2021</b> , 2021, 8891093                              | 4  |
| 854 | Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases. <b>2021</b> , 12, 640700  | 4  |
| 853 | HMGB1 regulates ferroptosis through Nrf2 pathway in mesangial cells in response to high glucose. <b>2021</b> , 41,  | 14 |

|     |   |    |
|-----|---|----|
| 852 | Outcomes of Kidney Donors With Impaired Fasting Glucose. <b>2021,</b>   | 1  |
| 851 | Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. <b>2021,</b> | 0  |
| 850 | Bone Marrow Mesenchymal Stem Cells Ameliorate Cisplatin-Induced Renal Fibrosis miR-146a-5p/Tfdp2 Axis in Renal Tubular Epithelial Cells. <b>2020,</b> 11, 623693  | 5  |
| 849 | Microvascular Complications and Their Associated Risk Factors Among Rural Type 2 Diabetic Population: A Cross-Sectional Study. <b>2021,</b> 3, 625-631  |    |
| 848 | Novel biomarkers of diabetic kidney disease: current status and potential clinical application. <b>2021,</b> 58, 819-830  | 8  |
| 847 | Historical account of endocrinal disorders in Unani medicine. <b>2021,</b>  | 1  |
| 846 | Acute Kidney Injury and Progressive Diabetic Kidney Disease: An Epidemiological Perspective. <b>2021</b> , 14, 23-31  | 2  |
| 845 | Geroprotective effects of Alzheimer's disease drug candidates. <b>2021,</b> 13, 3269-3289   | 4  |
| 844 | The role of CDX2 in renal tubular lesions during diabetic kidney disease. <b>2021,</b> 13, 6782-6803  | 3  |
| 843 | Suramin enhances the urinary excretion of VEGF-A in normoglycemic and streptozotocin-induced diabetic rats. <b>2021,</b> 73, 841-846  | 2  |
| 842 | Clinical, histopathologic and molecular features of idiopathic and diabetic nodular mesangial sclerosis in humans. <b>2021,</b>   | 0  |
| 841 | Therapeutic transformation for diabetic kidney disease. <b>2021,</b> 99, 301-303  | 4  |
| 840 | The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. <b>2021,</b> 14,  | 15 |
| 839 | Activin A and Cell-Surface GRP78 Are Novel Targetable RhoA Activators for Diabetic Kidney Disease. <b>2021,</b> 22,   | 2  |
| 838 | PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review). <b>2021,</b> 21, 540  | 15 |
| 837 | Diabetic Kidney Disease Represents a Locus of Opportunity. <b>2021,</b> 12, 650503  |    |
| 836 | Fluorophore-Dapagliflozin Dyad for Detecting Diabetic Liver/Kidney Damages via Fluorescent Imaging and Treating Diabetes via Inhibiting SGLT2. <b>2021,</b> 93, 4647-4656   | 3  |
| 835 | Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus. <b>2021,</b> 45, 868-879   | 0  |

|     |   |   |
|-----|---|---|
| 834 | Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. <b>2021</b> , 20, 75   | 3 |
| 833 | A hyaluronan synthesis inhibitor delays the progression of diabetic kidney disease in a mouse experimental model. <b>2021</b> , 2, 809-818                                  |   |
| 832 | eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined.. <b>2021</b> , 2, 1042-1047  | 8 |
| 831 | Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD). <b>2021</b> , 11,  | 0 |
| 830 | Obstructive sleep apnea is associated with impaired renal function in patients with diabetic kidney disease. <b>2021</b> , 11, 5675   | 2 |
| 829 | Association between estimated glomerular filtration rate and clinical outcomes in ischemic stroke patients with high-grade carotid artery stenosis. <b>2021</b> , 21, 124   | 3 |
| 828 | -Lipoic Acid Increases Collagen Synthesis and Deposition in Nondiabetic and Diabetic Rat Kidneys. <b>2021</b> , 2021, 6669352   | 1 |
| 827 | [Kidney as pacemaker for cardiovascular aging]. <b>2021</b> , 146, 317-322  |   |
| 826 | MicroRNAs, Parkinson's Disease, and Diabetes Mellitus. <b>2021</b> , 22,  | 5 |
| 825 | Recent Highlights of Research on miRNAs as Early Potential Biomarkers for Cardiovascular Complications of Type 2 Diabetes Mellitus. <b>2021</b> , 22,                       | 7 |
| 824 | DIABETIC NEPHROPATHY: PREVALENCE AND RISK FACTORS. <b>2021</b> , 77, 3-11   | 1 |
| 823 | Network Pharmacology-Based Prediction of Mechanism of Shenzhuo Formula for Application to DKD. <b>2021</b> , 2021, 6623010  | 1 |
| 822 | The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <b>2021</b> , 23, 1652-1659 | 3 |
| 821 | The Value of Ketone Bodies in the Evaluation of Kidney Function in Patients with Type 2 Diabetes Mellitus. <b>2021</b> , 2021, 5596125                                      | 0 |
| 820 | Common genetic variants and pathways in diabetes and associated complications and vulnerability of populations with different ethnic origins. <b>2021</b> , 11, 7504        | 3 |
| 819 | Urinary adiponectin excretion is an early predictive marker of the decline of the renal function in patients with diabetes mellitus. <b>2021</b> , 35, 107848               | 2 |
| 818 | Identification of Lumican and Fibromodulin as Hub Genes Associated with Accumulation of Extracellular Matrix in Diabetic Nephropathy. <b>2021</b> , 46, 275-285             | 2 |
| 817 | DsbA-L Ameliorates Renal Injury Through the AMPK/NLRP3 Inflammasome Signaling Pathway in Diabetic Nephropathy. <b>2021</b> , 12, 659751                                     | 4 |

|     |  |   |
|-----|--|---|
| 816 | Non-Coding RNA and Diabetic Kidney Disease. <b>2021</b> , 40, 553-567  | 9 |
| 815 | Glomerular Diseases in Diabetic Patients: Implications for Diagnosis and Management. <b>2021</b> , 10,   | 2 |
| 814 | Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy. <b>2021</b> , 101, 935-941  | 3 |
| 813 | Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy. <b>2021</b> , 28, 1003-1024   | 3 |
| 812 | Vitamin D/VDR Protects Against Diabetic Kidney Disease by Restoring Podocytes Autophagy. <b>2021</b> , 14, 1681-1693   | 4 |
| 811 | The combination of soluble tumor necrosis factor receptor type 1 and fibroblast growth factor 21 exhibits better prediction of renal outcomes in patients with type 2 diabetes mellitus. <b>2021</b> , 44, 2609-2619 | 2 |
| 810 | Kidney Outcomes With SGLT-2 Inhibitors. <b>2021</b> , 9, 12-15   |   |
| 809 | Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes. <b>2021</b> , 12, 1613-1630  | 1 |
| 808 | PodoCount: A robust, fully automated whole-slide podocyte quantification tool.   | 1 |
| 807 | Tailoring the management of hypertension to comorbidities. <b>2021</b> , 36, 405-412   | 0 |
| 806 | Based on Network Pharmacology and Molecular Docking to Explore the Underlying Mechanism of Huangqi Gegen Decoction for Treating Diabetic Nephropathy. <b>2021</b> , 2021, 9928282                                    | 4 |
| 805 | The determinants of complication trajectories in American Indians with type 2 diabetes. <b>2021</b> , 6,   | 1 |
| 804 | The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis. <b>2021</b> , 31, 1365-1374                                       | 2 |
| 803 | Tacrolimus Protects Podocytes from Apoptosis via Downregulation of TRPC6 in Diabetic Nephropathy. <b>2021</b> , 2021, 8832114  | 2 |
| 802 | Adipose triglyceride lipase protects renal cell endocytosis in a Drosophila dietary model of chronic kidney disease. <b>2021</b> , 19, e3001230  | 4 |
| 801 | Altered Renal Pathology in an Autoimmune Disease Mouse Model After Induction of Diabetes Mellitus. <b>2021</b> , 27, 897-909   |   |
| 800 | An updated pharmacological insight of resveratrol in the treatment of diabetic nephropathy. <b>2021</b> , 780, 145532  | 9 |
| 799 | Phelligrudin D from <i>Inonotus obliquus</i> attenuates oxidative stress and accumulation of ECM in mesangial cells under high glucose via activating Nrf2. <b>2021</b> , 75, 1021-1029                              | 1 |

|     |  |    |
|-----|--|----|
| 798 | Retrospective Analysis of the Clinical Characteristics of Infection Worldwide From 2009 to 2020. <b>2021</b> , 12, 658329  | 7  |
| 797 | Carbon monoxide alleviates senescence in diabetic nephropathy by improving autophagy. <b>2021</b> , 54, e13052   | 2  |
| 796 | Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?. <b>2021</b> , 18,   | 2  |
| 795 | The Role of Finerenone in the Management of Diabetic Nephropathy. <b>2021</b> , 12, 1791-1797  | 4  |
| 794 | Rescue effect of sodium acetate in diabetes mellitus-associated testicular dysfunction is accompanied by PCSK9 modulation. <b>2021</b> , 184, 52-62                                      | 5  |
| 793 | A qualitative study documenting unmet needs in the management of diabetic kidney disease (DKD) in the primary care setting. <b>2021</b> , 21, 930  | 2  |
| 792 | Newer drug treatments for type 2 diabetes. <b>2021</b> , 373, n1171  | 2  |
| 791 | Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites in modulation of renal inflammation and disease progression. <b>2021</b> , 35, 101484 | 7  |
| 790 | Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. <b>2021</b> , 22,  | 7  |
| 789 | Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease. <b>2021</b> , 5, bvab083  | 1  |
| 788 | Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice. <b>2021</b> ,  | 2  |
| 787 | KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. <b>2021</b> , 33, 1042-1061.e7   | 17 |
| 786 | Associations Between Obesity and Kidney Disease in Chinese Men and Women With Type 2 Diabetes: A Retrospective Cohort Study. <b>2021</b> ,   | 0  |
| 785 | Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. <b>2021</b> , 35, 107880                                  | 2  |
| 784 | Sex differences in soluble prorenin receptor in patients with type 2 diabetes. <b>2021</b> , 12, 33  | 1  |
| 783 | Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus. <b>2021</b> ,   | 2  |
| 782 | Hemodialysis-Related Glycemic Disarray Proven by Continuous Glucose Monitoring; Glycemic Markers and Hypoglycemia. <b>2021</b> , 44, 1647-1656   | 3  |
| 781 | Acetate ameliorates nephrotoxicity in streptozotocin-nicotinamide-induced diabetic rats: Involvement of xanthine oxidase activity. <b>2021</b> , 142, 155501                             | 4  |

|     |   |    |
|-----|---|----|
| 780 | Clinical Impact of Combination Therapy in Diabetic Neuropathy and Nephropathy. <b>2021</b> , 3471-3480  | 1  |
| 779 | A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial.. <b>2021</b> , 2, 1240-1250   | 1  |
| 778 | Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. <b>2021</b> , 14,  | 5  |
| 777 | High glucose-induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model. <b>2021</b> , 41,                              | 0  |
| 776 | Perspectives on the Role of Magnetic Resonance Imaging (MRI) for Noninvasive Evaluation of Diabetic Kidney Disease. <b>2021</b> , 10,   | 3  |
| 775 | PPAR- $\alpha$ Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice. <b>2021</b> , 8, 652558                   | 3  |
| 774 | Trimethylamine N-Oxide Exacerbates Renal Inflammation and Fibrosis in Rats With Diabetic Kidney Disease. <b>2021</b> , 12, 682482   | 12 |
| 773 | How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR. <b>2021</b> , 10,   | 4  |
| 772 | Bioinformatics Analysis Reveals Crosstalk Among Platelets, Immune Cells, and the Glomerulus That May Play an Important Role in the Development of Diabetic Nephropathy. <b>2021</b> , 8, 657918 | 1  |
| 771 | Alzheimer's disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links. <b>2021</b> , 12, 745-766  | 7  |
| 770 | Diabetes mellitus is a risk factor of acute kidney injury in liver transplantation patients. <b>2021</b> , 20, 215-221  | 2  |
| 769 | DETERMINING THE POSSIBLE EFFECT OF DIABETES ON THE NUTRITIONAL STATUS OF HEMODIALYSIS PATIENTS.   |    |
| 768 | Sexual dimorphism in the progression of type 2 diabetic kidney disease in T2DN rats. <b>2021</b> , 53, 223-234  | 1  |
| 767 | Prevalence and determinants of Impaired Serum Creatinine and Urea among type 2 diabetic patients of jimma medical center, Jimma, Southwestern Ethiopia, 2019. <b>2021</b> , 3, 100096           | 0  |
| 766 | Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. <b>2021</b> , 25, 1070-1078 | 4  |
| 765 | Breaking New Ground with Incretin Therapy in Diabetes. <b>2021</b> , 385, 560-561   | 2  |
| 764 | Noninvasive Evaluation of Renal Hypoxia by Multiparametric Functional MRI in Early Diabetic Kidney Disease. <b>2021</b> ,   | 0  |
| 763 | Vaccination Against Receptor for Advanced Glycation End Products Attenuates the Progression of Diabetic Kidney Disease. <b>2021</b> , 70, 2147-2158   | 5  |



|     |  |    |
|-----|--|----|
| 762 | Association of SIRT6 circulating levels with urinary and glycometabolic markers in pre-diabetes and diabetes. <b>2021</b> , 58, 1551-1562  | 1  |
| 761 | Acute Kidney Injury in Pediatric Diabetic Kidney Disease. <b>2021</b> , 9, 668033  | 2  |
| 760 | Manifestation of rs1888747 polymorphisms in the FRMD3 gene in diabetic kidney disease and diabetic retinopathy in type 2 diabetes patients. <b>2021</b> , 40, 263-271  |    |
| 759 | Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial (Preprint).   |    |
| 758 | Identification and construction of lncRNA-associated ceRNA network in diabetic kidney disease. <b>2021</b> , 100, e26062   | 1  |
| 757 | Nephron-deficient HSRA rats exhibit renal injury with age but have limited renal damage from streptozotocin-induced hyperglycemia. <b>2021</b> , 320, F1093-F1105  | 1  |
| 756 | Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge. <b>2021</b> , 8, 654557   | 2  |
| 755 | Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease.  |    |
| 754 | Mitochondrial DNA-Mediated Inflammation in Acute Kidney Injury and Chronic Kidney Disease. <b>2021</b> , 2021, 9985603   | 1  |
| 753 | Targeting Canonical and Non-Canonical STAT Signaling Pathways in Renal Diseases. <b>2021</b> , 10,   | 3  |
| 752 | Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as novel risk markers for diabetic nephropathy in patients with type 2 diabetes. <b>2021</b> , 7, e07564   | 5  |
| 751 | Animal models of diabetes-associated vascular diseases: an update on available models and experimental analysis. <b>2021</b> ,   | 1  |
| 750 | Oral Health Messengers: Diabetes Mellitus Relevance. <b>2021</b> , 14, 3001-3015   | 4  |
| 749 | Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. <b>2021</b> , 6, 2575-2584 | 2  |
| 748 | WT1 and ACE mRNAs of blood extracellular vesicle as biomarkers of diabetic nephropathy. <b>2021</b> , 19, 299  | 4  |
| 747 | Renal function in patients following a low carbohydrate diet for type 2 diabetes: a review of the literature and analysis of routine clinical data from a primary care service over 7 years. <b>2021</b> , 28, 469-479                   | 2  |
| 746 | Glycemic Variability and KIM-1-Induced Inflammation in the Diabetic Kidney. <b>2021</b> , 70, 1617-1619  | 1  |
| 745 | Signaling Pathways Involved in Diabetic Renal Fibrosis. <b>2021</b> , 9, 696542  | 10 |

|     |   |    |
|-----|---|----|
| 744 | The role of inflammation in diabetic kidney disease. <b>2021</b> , 36, 753-766  | 5  |
| 743 | Real-World Diagnosis and Treatment of Diabetic Kidney Disease. <b>2021</b> , 38, 4425-4441  | 1  |
| 742 | Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. <b>2021</b> , 2021, 1497449   | 39 |
| 741 | Warm ischemia time length during on-clamp partial nephrectomy: dose it really matter?. <b>2021</b> ,  | 3  |
| 740 | Quantitative Analysis of Different Multi-Wavelength PPG Devices and Methods for Noninvasive In-Vivo Estimation of Glycated Hemoglobin. <b>2021</b> , 11, 6867   | 0  |
| 739 | Role of Dendritic Cell in Diabetic Nephropathy. <b>2021</b> , 22,   | 0  |
| 738 | Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial. <b>2021</b> , | 0  |
| 737 | The effects of probiotic supplementation on renal function, inflammation, and oxidative stress in diabetic nephropathy: A systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 11, 1122-1131  | 2  |
| 736 | Glycemic control outcome in patients with type 2 diabetes mellitus: chronic care management support of family care team in Thailand.. <b>2021</b> , 20, 1269-1279   | 0  |
| 735 | Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. <b>2021</b> , 17, 725-739  | 17 |
| 734 | Astragaloside IV ameliorates diabetic nephropathy in mice by inhibiting NLRP3 inflammasome-mediated inflammation. <b>2021</b> , 48,   | 4  |
| 733 | Reference genes for mesangial cell and podocyte qPCR gene expression studies under high-glucose and renin-angiotensin-system blocker conditions. <b>2021</b> , 16, e0246227   | 1  |
| 732 | Fibrosis, the Bad Actor in Cardiorenal Syndromes: Mechanisms Involved. <b>2021</b> , 10,  | 1  |
| 731 | Creatine Supplementation in Type 2 Diabetic Patients: A Systematic Review of Randomized Clinical Trials.. <b>2021</b> ,   |    |
| 730 | Self-efficacy remains a vital factor in reducing the risk of dialysis in type 2 diabetes care. <b>2021</b> , 100, e26644  |    |
| 729 | Factors associated with relative muscle strength in patients with type 2 diabetes mellitus. <b>2021</b> , 95, 104384  | 2  |
| 728 | DNA Methylation Changes Associated With Type 2 Diabetes and Diabetic Kidney Disease in an East Asian Population. <b>2021</b> , 106, e3837-e3851   | 2  |
| 727 | Role of Cellular Senescence in Type II Diabetes. <b>2021</b> , 162,   | 3  |

|     |  |    |
|-----|--|----|
| 726 | VDR/Atg3 Axis Regulates Slit Diaphragm to Tight Junction Transition via p62-Mediated Autophagy Pathway in Diabetic Nephropathy. <b>2021</b> , 70, 2639-2651  | 2  |
| 725 | Morroniside Promotes PGC-1-Mediated Cholesterol Efflux in Sodium Palmitate or High Glucose-Induced Mouse Renal Tubular Epithelial Cells. <b>2021</b> , 2021, 9942152                               | 1  |
| 724 | A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. <b>2021</b> , 14, 3567-3602   | 18 |
| 723 | Brij-functionalized chitosan nanocarrier system enhances the intestinal permeability of P-glycoprotein substrate-like drugs. <b>2021</b> , 266, 118112   | 1  |
| 722 | Modified arteriosclerosis score predicts the outcomes of diabetic kidney disease. <b>2021</b> , 22, 281  | 1  |
| 721 | Urinary small extracellular vesicles derived CCL21 mRNA as biomarker linked with pathogenesis for diabetic nephropathy. <b>2021</b> , 19, 355  | 5  |
| 720 | Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial. <b>2021</b> , 10, e31061                                     | 1  |
| 719 | PRKAA2 variation and the clinical characteristics of patients newly diagnosed with type 2 diabetes mellitus in Yogyakarta, Indonesia. <b>2021</b> , 15, 161-170                                    | 1  |
| 718 | Chronic kidney disease. <b>2021</b> , 398, 786-802   | 73 |
| 717 | Mapping the genetic architecture of human traits to cell types in the kidney identifies mechanisms of disease and potential treatments. <b>2021</b> , 53, 1322-1333                                | 7  |
| 716 | mitigates microvascular complications of type 2 diabetes mellitus: the involvement of oxidative stress and aldose reductase. <b>2021</b> ,   |    |
| 715 | Inhibition of Renal Tubular Epithelial Mesenchymal Transition and Endoplasmic Reticulum Stress-Induced Apoptosis with Shenkang Injection Attenuates Diabetic Tubulopathy. <b>2021</b> , 12, 662706 | 1  |
| 714 | Single Cell Transcriptome Helps Better Understanding Crosstalk in Diabetic Kidney Disease. <b>2021</b> , 8, 657614   | 0  |
| 713 | Anthropometric Measures and Incident Diabetic Nephropathy in Participants With Type 2 Diabetes Mellitus. <b>2021</b> , 12, 706845  | 1  |
| 712 | Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model. <b>2021</b> , 22, 287   | 0  |
| 711 | Cardiometabolic and Kidney Protection in Kidney Transplant Recipients with Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. <b>2021</b> ,                              | 2  |
| 710 | Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure. <b>2021</b> , 2,   | 0  |
| 709 | Novel Therapies for Kidney Disease in People with Diabetes. <b>2021</b> ,  | 0  |

|     |   |   |
|-----|---|---|
| 708 | Yiqi Huoxue Recipe Regulates Autophagy through Degradation of Advanced Glycation End Products via mTOR/S6K1/LC3 Pathway in Diabetic Nephropathy. <b>2021</b> , 2021, 9942678            |   |
| 707 | SIRT1: a promising therapeutic target in type 2 diabetes mellitus. <b>2021</b> , 1-16   | 1 |
| 706 | Activated Alpha 2-Macroglobulin Is a Novel Mediator of Mesangial Cell Profibrotic Signaling in Diabetic Kidney Disease. <b>2021</b> , 9,  | 0 |
| 705 | Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. <b>2021</b> , 64, 2147-2158   | 9 |
| 704 | Berberine Acts on C/EBP $\beta$ /lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells. <b>2021</b> , 12, 675834                                       | 0 |
| 703 | Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up. <b>2021</b> , 13, 20081-20093  |   |
| 702 | Comparison of the effects of frequent versus conventional nutritional interventions in patients with type 2 diabetes mellitus: A randomized, controlled trial. <b>2021</b> ,            | 1 |
| 701 | CHIP-overexpressing Wharton's jelly-derived mesenchymal stem cells attenuate hyperglycemia-induced oxidative stress-mediated kidney injuries in diabetic rats. <b>2021</b> , 173, 70-80 | 0 |
| 700 | Serum netrin and VCAM-1 as biomarker for Egyptian patients with type II diabetes mellitus. <b>2021</b> , 27, 101045   | 2 |
| 699 | Exosomes: Advances, development and potential therapeutic strategies in diabetic nephropathy. <b>2021</b> , 122, 154834   | 7 |
| 698 | Long non-coding RNA XIST promoted cell proliferation and suppressed apoptosis by miR-423-5p/HMGA2 axis in diabetic nephropathy. <b>2021</b> , 476, 4517-4528                            | 1 |
| 697 | Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta-analysis. <b>2021</b> ,  | 1 |
| 696 | Efficacy and safety of acupuncture combined with Chinese Herbal Medicine for diabetic nephropathy: A protocol for systematic review and meta-analysis. <b>2021</b> , 100, e27087        | 1 |
| 695 | Urinary sediment CCL5 messenger RNA as a potential prognostic biomarker of diabetic nephropathy.. <b>2022</b> , 15, 534-544   | 1 |
| 694 | Identification of Key Candidate Genes and Chemical Perturbagens in Diabetic Kidney Disease Using Integrated Bioinformatics Analysis. <b>2021</b> , 12, 721202                           | 3 |
| 693 | Prevention of Microvascular Complications of Diabetes. <b>2021</b> , 50, 431-455  | 2 |
| 692 | Impaired Nicotinamide Adenine Dinucleotide Biosynthesis in the Kidney of Chronic Kidney Disease. <b>2021</b> , 12, 723690   | 3 |
| 691 | Qing-Re-Xiao-Zheng Formula Modulates Gut Microbiota and Inhibits Inflammation in Mice With Diabetic Kidney Disease. <b>2021</b> , 8, 719950   | 2 |

|     |  |    |
|-----|--|----|
| 690 | Chronic Kidney Disease: Strategies to Retard Progression. <b>2021</b> , 22,  | 3  |
| 689 | Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity. <b>2021</b> , 81, 3708-3730   | 12 |
| 688 | Mechanism of Cordyceps Cicadae in Treating Diabetic Nephropathy Based on Network Pharmacology and Molecular Docking Analysis. <b>2021</b> , 2021, 5477941  | 1  |
| 687 | Clinical and Histological Predictors of Renal Survival in Patients with Biopsy-Proven Diabetic Nephropathy.. <b>2022</b> , 8, 93-101   | 0  |
| 686 | Assessing diabetes mellitus knowledge among Syrian medical students: A cross-sectional study. <b>2021</b> , 7, e08079  | 0  |
| 685 | Quantification of sweat urea in diabetes using electro-optical technique. <b>2021</b> , 42,  | 1  |
| 684 | Epidemiological characteristics of diabetic kidney disease in Taiwan. <b>2021</b> ,  | 0  |
| 683 | Exploring the Potential Mechanism of Tang-Shen-Ning Decoction against Diabetic Nephropathy Based on the Combination of Network Pharmacology and Experimental Validation. <b>2021</b> , 2021, 1025053   | 0  |
| 682 | Identification of Diabetic Nephropathy in Patients Undergoing Kidney Biopsy through Blood and Urinary Profiles of d-Serine.. <b>2021</b> , 2, 1734-1742  | 0  |
| 681 | Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials. <b>2021</b> , 22, 304   | 3  |
| 680 | Pathologic Diabetic Nephropathy in Autopsied Diabetic Cases With Normoalbuminuria From a Japanese Community-Based Study.. <b>2021</b> , 6, 3035-3044   | 2  |
| 679 | Wnt/ $\beta$ -catenin pathway proteins in end-stage renal disease. <b>2021</b> , 15, 1423-1434   | 0  |
| 678 | Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?. <b>2021</b> , 908, 174378  | 0  |
| 677 | Urine Albumin-Creatinine ratio is associated with prognosis in patients with diabetic foot osteomyelitis. <b>2021</b> , 180, 109043  | 0  |
| 676 | Sodium-glucose cotransporter 2 inhibitors benefit to kidney and cardiovascular outcomes for patients with type 2 diabetes mellitus and chronic kidney disease 3b-4: A systematic review and meta-analysis of randomized clinical trials. <b>2021</b> , 180, 109033 | 2  |
| 675 | Tinospora cordifolia activates PPAR $\gamma$ pathway and mitigates glomerular and tubular cell injury in diabetic kidney disease. <b>2021</b> , 91, 153663   | 0  |
| 674 | Therapeutic potential of pro-resolving mediators in diabetic kidney disease. <b>2021</b> , 178, 113965   | 2  |
| 673 | Stem cell therapies in diabetes. <b>2022</b> , 201-210   |    |

|     |  |    |
|-----|--|----|
| 672 | Endogenous antiinflammatory and proresolving lipid mediators in renal disease. <b>2022</b> , 55-67   | 0  |
| 671 | Therapy approaches in diabetic nephropathy (review of literature). <b>2021</b> , 25, 18-30   | 1  |
| 670 | A Phase IIb Randomized Controlled Trial Investigating the Effects of Tocotrienol-Rich Vitamin E on Diabetic Kidney Disease. <b>2021</b> , 13,  | 8  |
| 669 | Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase $\alpha$ (AMPK) in renal glomerular endothelial cells. <b>2021</b> , 12, 4805-4815 | 3  |
| 668 | Relationship between the FTO Genotype and Early Chronic Kidney Disease in Type 2 Diabetes: The Mediating Role of Central Obesity, Hypertension, and High Albuminuria. <b>2021</b> , 14, 73-80  | 0  |
| 667 | NRF2: A potential target for the treatment of diabetic nephropathy. <b>2021</b> , 1, 27-32   |    |
| 666 | SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. <b>2021</b> , 23, 475-491   | 4  |
| 665 | Diabetic Kidney Disease, Endothelial Damage, and Podocyte-Endothelial Crosstalk. <b>2021</b> , 3, 105-115  | 18 |
| 664 | Serum stromal cell-derived factor-1 levels are associated with diabetic kidney disease in type 2 diabetic patients. <b>2021</b> , 68, 1101-1107  | 0  |
| 663 | Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression. <b>2021</b> , 12, 268-276       | 0  |
| 662 | Relations Between Urinary Albumin Excretion and a Dietary Intake of Fruits in Patients With Type 2 Diabetes. <b>2021</b> , 13, 151-157   |    |
| 661 | Evaluation of the Genetic Association and Expressions of Notch-2 /Jagged-1 in Patients with Type 2 Diabetes Mellitus. <b>2021</b> , 75, 101-108  | 0  |
| 660 | Serum Total Bilirubin and Progression of Chronic Kidney Disease and Mortality: A Systematic Review and Meta-Analysis. <b>2020</b> , 7, 549   | 0  |
| 659 | Role of Glucose Metabolism and Mitochondrial Function in Diabetic Kidney Disease. <b>2021</b> , 21, 6  | 2  |
| 658 | Scopoletin and umbelliferone from Cortex Mori as protective agents in high glucose-induced mesangial cell as model of diabetic glomerulosclerosis. <b>2021</b> , 64, 150-158   | 0  |
| 657 | Efficacy, safety and response predictors of adjuvant astragalus for diabetic kidney disease (READY): study protocol of an add-on, assessor-blind, parallel, pragmatic randomised controlled trial. <b>2021</b> , 11, e042686   | 4  |
| 656 | A novel polysaccharide obtained from alleviates inflammatory responses in a diabetic nephropathy mouse model the TLR4-NF- $\kappa$ B pathway. <b>2021</b> , 12, 9054-9065  | 3  |
| 655 | Inflammasome activation in podocytes: a new mechanism of glomerular diseases. <b>2020</b> , 69, 731-743  | 16 |

|     |  |    |
|-----|--|----|
| 654 | SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. <b>2020</b> , 11, 2757-2774  | 6  |
| 653 | Ergosterol ameliorates renal inflammatory responses in mice model of diabetic nephropathy. <b>2020</b> , 128, 110252   | 11 |
| 652 | Specialized pro-resolving mediators in diabetes: novel therapeutic strategies. <b>2019</b> , 133, 2121-2141  | 7  |
| 651 | The mechanobiology of kidney podocytes in health and disease. <b>2020</b> , 134, 1245-1253   | 3  |
| 650 | Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease. <b>2020</b> , 117, 29013-29024  | 11 |
| 649 | HyPR-seq: Single-cell quantification of chosen RNAs via hybridization and sequencing of DNA probes. <b>2020</b> , 117, 33404-33413   | 7  |
| 648 | Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development. <b>2021</b> , 30, 85-93  | 3  |
| 647 | Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study. <b>2021</b> , 14, 1657-1664  | 1  |
| 646 | Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. <b>2021</b> , 7, 104-111  | 7  |
| 645 | Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?. <b>2020</b> , 35, i48-i55   | 9  |
| 644 | Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?. <b>2020</b> , 35, i33-i42   | 24 |
| 643 | Mapping the genetic architecture of human traits to cell types in the kidney identifies mechanisms of disease and potential treatments.  | 1  |
| 642 | Adipose Triglyceride Lipase protects the endocytosis of renal cells on a high fat diet in Drosophila.  | 1  |
| 641 | Protective Role of Tangshen Formula on the Progression of Renal Damage in Mice by TRPC6/Talin1 Pathway in Podocytes. <b>2020</b> , 2020, 3634974   | 2  |
| 640 | Albumin Overload and PINK1/Parkin Signaling-Related Mitophagy in Renal Tubular Epithelial Cells. <b>2018</b> , 24, 1258-1267   | 2  |
| 639 | Clustering of Mental and Physical Comorbidity and the Risk of Frailty in Patients Aged 60 Years or More in Primary Care. <b>2019</b> , 25, 6820-6835   | 11 |
| 638 | The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy. <b>2018</b> , 13, e0192800   | 7  |
| 637 | Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center. <b>2019</b> , 11, 267-274 | 13 |

|     |   |    |
|-----|---|----|
| 636 | A case of type B insulin resistance syndrome treated with low-dose glucocorticoids. <b>2019</b> , 2019,   | 3  |
| 635 | Physical exercise associated with vitamin D chronic supplementation reduces kidney injury induced by monosodium glutamate. <b>2020</b> , 92, e20201097  | 1  |
| 634 | Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists. <b>2020</b> , 16, 80   | 1  |
| 633 | [Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis]. <b>2019</b> , 59, 76-87   | 6  |
| 632 | Inflammatory proteins in diabetic kidney disease-potential as biomarkers and therapeutic targets. <b>2019</b> , 7, S243   | 3  |
| 631 | Glycation and Antioxidants: Hand in the Glove of Antiglycation and Natural Antioxidants. <b>2020</b> , 21, 899-915  | 5  |
| 630 | Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <b>2020</b> , 43, 1803-1812   | 20 |
| 629 | Effects of fermented red bean extract on nephropathy in streptozocin-induced diabetic rats. <b>2020</b> , 64,   | 2  |
| 628 | A Novel Approach Based on Metabolomics Coupled With Intestinal Flora Analysis and Network Pharmacology to Explain the Mechanisms of Action of Bekhogainsam Decoction in the Improvement of Symptoms of Streptozotocin-Induced Diabetic Nephropathy in Mice. <b>2020</b> , 11, 633 | 7  |
| 627 | Oxidative Stress Markers in Chronic Kidney Disease with Emphasis on Diabetic Nephropathy. <b>2020</b> , 9,  | 19 |
| 626 | Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy. <b>2021</b> ,   | 1  |
| 625 | Urine extracellular vesicles capture kidney transcriptome and hyperglycemia linked mRNA signatures for type 1 diabetic kidney disease.  |    |
| 624 | Diabetic Kidney Disease. <b>2022</b> , 87-102   |    |
| 623 | Loss of Functional SCO2 Attenuates Oxidative Stress in Diabetic Kidney Disease. <b>2021</b> ,   | 0  |
| 622 | Modulating effects of capsaicin on glucose homeostasis and the underlying mechanism. <b>2021</b> , 1-19   | 1  |
| 621 | Eficacia y seguridad de la semaglutida en un paciente diabético y obeso en hemodiálisis incremental. ¿Contribuye también a preservar la función renal residual?. <b>2021</b> ,  |    |
| 620 | Lipotoxic Proximal Tubular Injury: A Primary Event in Diabetic Kidney Disease. <b>2021</b> , 8, 751529  | 1  |
| 619 | Skin autofluorescence is associated with progression of kidney disease in type 2 diabetes: A prospective cohort study from the Hong Kong diabetes biobank.. <b>2021</b> ,   | 2  |



|     |  |   |
|-----|--|---|
| 618 | Multipollutant, longitudinal analysis of the association between urinary tungsten and incident diabetes in a rural population.. <b>2021</b> , 5, e173  | 1 |
| 617 | Repression of HDAC5 by acetate restores hypothalamic-pituitary-ovarian function in type 2 diabetes mellitus. <b>2021</b> , 106, 69-81  | 2 |
| 616 | Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific?. <b>2021</b> , 12, 1765-1777   |   |
| 615 | Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <b>2021</b> , 59, 309              | 0 |
| 614 | SGLT2i agonist plus GLP-1 receptor COMBination therapy in type 2 diabetes: a renal (KIDney) endpoints real world study-(COMBi-KID Study). (Preprint).  |   |
| 613 | Association of Predicted Lean Body Mass and Fat Mass With Incident Diabetic Nephropathy in Participants With Type 2 Diabetes Mellitus: A Post Hoc Analysis of ACCORD Trial. <b>2021</b> , 12, 719666 | 0 |
| 612 | Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes. <b>2021</b> , 12, 3093-3105   | 0 |
| 611 | The Profile and Function of Gut Microbiota in Diabetic Nephropathy. <b>2021</b> , 14, 4283-4296  | 2 |
| 610 | Raman spectroscopy of urinary extracellular vesicles to stratify patients with chronic kidney disease in type 2 diabetes. <b>2022</b> , 39, 102468   | 4 |
| 609 | Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease. cd210078  |   |
| 608 | Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK. <b>2021</b> , 9,         | 3 |
| 607 | Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial. <b>2021</b> , 9, 727-728  |   |
| 606 | Proteinuria as a significant predictive factor for the progression of carotid artery atherosclerosis in non-albuminuric type 2 diabetes. <b>2021</b> , 181, 109082                                   |   |
| 605 | Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus. <b>2018</b> , 90, 59-64  | 1 |
| 604 | Modification by Ethanol and Taurine, Singly and in Combination, of Changes in Indices of Renal Dysfunction Caused by Diabetes in Rats. <b>2019</b> , 1155, 369-380                                   |   |
| 603 | Prise en charge de la maladie rénale diabétique. <b>2019</b> , 313-343   |   |
| 602 | Chronic Kidney Disease, Common Comorbidities, and Diabetes. <b>2019</b> , 249-263  |   |
| 601 | Exploring the role of the metabolite-sensing receptor GPR109a in diabetic nephropathy.   |   |

- 600 STORIA NATURALE DELLA MALATTIA RENALE NEL DIABETE E TRATTAMENTO DELL'IPERGLICEMIA NEI PAZIENTI CON DIABETE DI TIPO 2 E RIDOTTA FUNZIONE RENALE. **2019**, 3,
- 599 The Association of UNC13B Gene Polymorphisms and Diabetic Kidney Disease in a Chinese Han Population. **2019**, 25, 8527-8533
- 598 Histological Examination of the Diabetic Kidney. **2020**, 2067, 63-87 3
- 597 Value of elastography point quantification in improving the diagnostic accuracy of early diabetic kidney disease. **2019**, 7, 3945-3956 3
- 596 Metabolic Disorder-Related Hypertension. **2020**, 507-545
- 595 Inflammatory Mechanisms in Diabetic Kidney Disease. **2020**, 437-455
- 594 Pyrroloquinoline Quinone Inhibits Oxidative Stress in Rats with Diabetic Nephropathy. **2020**, 26, e924372 3
- 593 Brief Review of Newer Antiglycemic Agents as Options in the Treatment of Diabetic Kidney Disease. **2020**, 7, 009-011
- 592 Application prospects of glucagon-like peptide-1 receptor agonists in treatment of metabolic diseases. **2020**, 28, 393-400
- 591 HyPR-seq: Single-cell quantification of chosen RNAs via hybridization and sequencing of DNA probes.
- 590 The Devil's in the Detail: The Importance of Specific, Descriptive Language for Reproducibility in Nutrition Science. **2020**, 30, 274-275 0
- 589 Diabetic kidney disease in primary care. **2020**, 61, 399-405 0
- 588 The possible antioxidant capabilities of formononetin in guarding against streptozotocin-induced diabetic nephropathy in rats. **2020**, 6, 3
- 587 Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. **2021**, 5
- 586 Impact of Albumin-to-Creatinine Ratio Point-of-Care Testing on the Diagnosis and Management of Diabetic Kidney Disease. **2021**, 19322968211054520
- 585 Mitochondria in Diabetic Kidney Disease. **2021**, 10, 4
- 584 Bayesian Age-Period-Cohort Prediction of Mortality of Type 2 Diabetic Kidney Disease in China: A Modeling Study. **2021**, 12, 767263 2
- 583 Metabolic Dysfunction Biomarkers as Predictors of Early Diabetes. **2021**, 11, 1

- 582 Identification of Hub Genes and Potential ceRNA Networks of Diabetic Nephropathy by Weighted Gene Co-Expression Network Analysis. **2021**, 12, 767654 1
- 581 Defining the Proteomic and Phosphoproteomic Landscape of Circulating Extracellular Vesicles in the Diabetes Spectrum.
- 580 Serum integrative omics reveals the landscape of human diabetic kidney disease. **2021**, 54, 101367 3
- 579 Immune Modulation and Macrophage Polarization in the Pathogenesis of Pancreatic Dysfunction and Obesity. **2020**, 135-151
- 578 Alteraciones del metabolismo de la glucosa en donante y receptor. **2020**, 9, 99-103
- 577 Serum Carboxy Methyl Lysine, Insulin Resistance and Sensitivity in Type 2 Diabetes Mellitus and Diabetic Nephropathy Cases; an Observational Study. **2020**, 13, 1987-1992
- 576 Nondiabetic Renal Disease (NDRD) and Diabetic Kidney Disease (DKD). **2021**, 159-171
- 575 Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.. **2021**, 33
- 574 Recent Advances in Nephropathy Biomarker Detections Using Paper-based Analytical Devices. **2021**,
- 573 Do You Have Any Risk Factors or Long-Term Health Conditions? How Environment, Lifestyle and Other Medical Conditions Are Linked to Kidney Disease. **2020**, 67-86
- 572 Early diagnosis of renal dysfunction in hypertensive patients with type 2 diabetes mellitus. **2020**, 11, 102-109 1
- 571 Modifiable factors related to 7-year renal outcomes in subjects with type 2 diabetes and chronic kidney disease stage 3. **2020**, 66, 187-193 1
- 570 Diabetic kidney disease: seven questions. **2020**, 63, 6
- 569 Prognostic Imaging Biomarkers for Diabetic Kidney Disease (iBEAt): Study protocol.
- 568 Optical imaging to assess the early metabolic response of rat kidney to uninephrectomy. **2020**,
- 567 The Genetic Basis of Diabetic Kidney Disease. **2020**, 221-235
- 566 Risk factors for the development of cardiovascular diseases in patients undergoing hemodialysis. **2020**, 17, 33-41
- 565 Effect of a sodium restriction diet on albuminuria and blood pressure in diabetic kidney disease patients: a meta-analysis. **2021**, 1 0

|     |   |    |
|-----|---|----|
| 564 | Diabetic ketoacidosis causes chronic elevation in renal C-C motif chemokine ligand 5. <b>2021</b> , 1   | 0  |
| 563 | Economic Impact and Health Care Utilization Outcomes of Diabetes Self-Management Education and Support Interventions for Persons With Diabetes: A Systematic Review and Recommendations for Future Research. <b>2021</b> , 26350106211047565  | 0  |
| 562 | Exercise Ameliorates Diabetic Kidney Disease in Type 2 Diabetic Fatty Rats. <b>2021</b> , 10,   | 1  |
| 561 | Correlation of Renal Profiles with Choroidal Vascularity Index in Eyes with Diabetic Retinopathy. <b>2021</b> , 10,   |    |
| 560 | Nephroprotective Effect of the Virgin Olive Oil Polyphenol Hydroxytyrosol in Type 1-like Experimental Diabetes Mellitus: Relationships with Its Antioxidant Effect. <b>2021</b> , 10,   | 0  |
| 559 | Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review.. <b>2021</b> , 13, e19325  | 0  |
| 558 | The Use of 'Omics for Diagnosing and Predicting Progression of Chronic Kidney Disease: A Scoping Review. <b>2021</b> , 12, 682929   | 3  |
| 557 | Sitagliptin's renoprotective effect in a diabetic nephropathy model in rats: The potential role of PI3K/AKT pathway. <b>2021</b> ,  | 0  |
| 556 | Single cell transcriptomics reveal disrupted kidney filter cell-cell interactions after early and selective podocyte injury.  | 1  |
| 555 | Comparison of clinical features and outcomes in peritoneal dialysis-associated peritonitis patients with and without diabetes: A multicenter retrospective cohort study. <b>2020</b> , 11, 435-446  | 3  |
| 554 | Kidney Disease: Improving Global Outcomes (KDIGO) New Guideline for Diabetes Management in Chronic Kidney Disease: A Meet-the-Expert Session.   | 1  |
| 553 | Diabetic Kidney Disease. <b>2020</b> , 19, 110-139  |    |
| 552 | Diagnostic performance of renal ultrasonography in detecting chronic kidney disease of various severity. <b>2020</b> , 14, 195-202  |    |
| 551 | Huangqi-Danshen decoction alleviates diabetic nephropathy in mice by inhibiting PINK1/Parkin-mediated mitophagy. <b>2020</b> , 12, 989-998  | 12 |
| 550 | Combination of astragaloside IV and ACEi ameliorates renal injuries in db/db mice. <b>2020</b> , 13, 827-836  | 1  |
| 549 | Renal outcomes of diabetic patients treated with combination therapy of ACE inhibitors plus either thiazide diuretics or calcium channel blockers: comparative retrospective cohort study in Northwestern Ethiopia. <b>2021</b> , 11, e048442 |    |
| 548 | PACS-2 attenuates diabetic kidney disease via the enhancement of mitochondria-associated endoplasmic reticulum membrane formation. <b>2021</b> , 12, 1107   | 1  |
| 547 | Single cell transcriptomics reveal disrupted kidney filter cell-cell interactions after early and selective podocyte injury. <b>2021</b> ,  | 1  |

|     |  |   |
|-----|--|---|
| 546 | A Study on Correlation between Contrast-Enhanced Ultrasound Parameters and Pathological Features of Diabetic Nephropathy. <b>2021,</b>   | 1 |
| 545 | Association between Long Working Hours and Chronic Kidney Disease according to Diabetic Status: A Nationwide Study (Korean National Health and Nutrition Examination Survey 2010-2017). <b>2021,</b> 64, |   |
| 544 | Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals and recommendations. <b>2021,</b>  | 0 |
| 543 | Dysbiosis of the Human Urinary Microbiome and its Association to Diseases Affecting the Urinary System.. <b>2022,</b> 62, 153-166  | 0 |
| 542 | Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature. <b>2021,</b> 18, 14791641211058856   | 7 |
| 541 | When Heart Failure Collides with Diabetes and Chronic Kidney Disease: Challenges and Opportunities. <b>2021,</b>   | 1 |
| 540 | The complement pathway: New insights into immunometabolic signalling in diabetic kidney disease. <b>2021,</b>  | 1 |
| 539 | Optical angiography for diabetes-induced pathological changes in microvascular structure and function: An overview.  | 2 |
| 538 | The role of the adaptive immune system in diabetic kidney disease (DKD). <b>2021,</b>  | 2 |
| 537 | Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. <b>2021,</b> 1  | 3 |
| 536 | Jujuboside A ameliorates high fat diet and streptozotocin induced diabetic nephropathy via suppressing oxidative stress, apoptosis, and enhancing autophagy. <b>2021,</b> 159, 112697                    | 2 |
| 535 | Nephroprotective Effects of Synthetic Flavonoid Hidrosmin in Experimental Diabetic Nephropathy.. <b>2021,</b> 10,  | 0 |
| 534 | Incretins in the Therapy of Diabetic Kidney Disease. <b>2021,</b> 22,  | 1 |
| 533 | Association of Acute Kidney Injury During Diabetic Ketoacidosis With Risk of Microalbuminuria in Children With Type 1 Diabetes. <b>2021,</b>   | 2 |
| 532 | Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. <b>2021,</b>                      | 6 |
| 531 | Ferulic Acid Attenuates Renal Injury by Improving&nbsp;Autophagy&nbsp;to Inhibit&nbsp;the&nbsp;Inflammatory&nbsp;Response in Type 2 Diabetic Mice.   |   |
| 530 | Design and Modeling of Bioreactor Utilizing Electrophoresis and Di-electrophoresis Techniques for Regenerating Reabsorption Function of Human Kidney PCT in Microfluidics Environment. <b>2021,</b> PP,  | 1 |
| 529 | Natural Course (Stages/Evidence-Based Discussion). <b>2022,</b> 49-74  |   |

|     |   |   |
|-----|---|---|
| 528 | Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA). <b>2022</b> , 563-582  | 1 |
| 527 | L-ergothioneine; a potential adjuvant in the management of diabetic nephropathy. <b>2022</b> , 2, 100033  | 2 |
| 526 | Diabetische Nephropathie: Die neue Rolle der Niere.   |   |
| 525 | Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists.. <b>2021</b> , 28, 337-346   | 0 |
| 524 | A Custom Target Next-Generation Sequencing 70-Gene Panel and Replication Study to Identify Genetic Markers of Diabetic Kidney Disease.. <b>2021</b> , 12,   | 1 |
| 523 | A perspective on nonsteroidal mineralocorticoid receptor antagonism in diabetic kidney disease. 10.34067/KID.00070720   |   |
| 522 | Diabetes modulation of the myocardial infarction- acute kidney injury axis.. <b>2022</b> ,  | 0 |
| 521 | Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease.. <b>2021</b> , 12, 757228                       | 2 |
| 520 | Salt loading with unilateral nephrectomy accelerates decline in glomerular filtration rate in the hypertensive, obese, type 2 diabetic SDT fatty rat model of diabetic kidney disease.. <b>2022</b> ,                   |   |
| 519 | MicroRNA-494-3p exacerbates renal epithelial cell dysfunction by targeting SOCS6 under high glucose treatment.. <b>2022</b> ,   | 0 |
| 518 | The Correlation between Thyroid Hormone Levels and the Kidney Disease Progression Risk in Patients with Type 2 Diabetes.. <b>2022</b> , 15, 59-67   | 1 |
| 517 | Repurposing a clinically approved prescription Colquhounia root tablet to treat diabetic kidney disease via suppressing PI3K/AKT/NF-kB activation.. <b>2022</b> , 17, 2   | 3 |
| 516 | Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors.. <b>2022</b> , 20, 2   | 1 |
| 515 | The effects of melatonin administration on carotid intima-media thickness and pulse wave velocity in diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.. <b>2022</b> , 48, 82-86               |   |
| 514 | The A allele of the rs759853 single nucleotide polymorphism in the gene confers risk for diabetic kidney disease in patients with type 2 diabetes from a Brazilian population.. <b>2022</b> ,                           | 0 |
| 513 | Astragalus mongholicus Bunge and Panax notoginseng formula (A&P) improves renal mesangial cell damage in diabetic nephropathy by inhibiting the inflammatory response of infiltrated macrophages.. <b>2022</b> , 22, 17 | 2 |
| 512 | Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?. <b>2022</b> , 15, 247-256  | 0 |
| 511 | Dyslipidemia and Diabetes. <b>2022</b> , 341-360  |   |

|     |  |   |
|-----|--|---|
| 510 | Kidney Transplantation and Kidney Pancreas Transplantation. <b>2022</b> , 417-429  |   |
| 509 | Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.. <b>2022</b> , | 0 |
| 508 | Ketoanalogue Supplementation in Patients with Non-Dialysis Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.. <b>2022</b> , 14,  | 0 |
| 507 | cAMP-response element binding protein mediates podocyte injury in diabetic nephropathy by targeting lncRNA DLX6-AS1.. <b>2022</b> , 155155   | 2 |
| 506 | Hyperactivation of YAP/TAZ drives alterations in mesangial cells through stabilization of N-MYC in diabetic nephropathy.   |   |
| 505 | Subtle morpho-functional kidney changes in type-2 diabetes mellitus patients: A duplex ultrasound assessment.. <b>2022</b> , 38, 674-681   |   |
| 504 | Fatty kidney: A possible future for chronic kidney disease research.. <b>2022</b> , e13748   | 0 |
| 503 | Effect of Polysaccharide on Decreasing Serum Amyloid A3 Expression through Inhibiting NF-B Activation in a Mouse Model of Diabetic Nephropathy.. <b>2022</b> , 2022, 7847135                   |   |
| 502 | The role of endothelial biomarkers in predicting damp-heat syndrome in diabetic kidney disease. <b>2022</b> , 9, 34-39   |   |
| 501 | Long non-coding RNAs as emerging regulators of miRNAs and epigenetics in diabetes-related chronic kidney disease.. <b>2022</b> , 1-12  | 0 |
| 500 | Acute effects of linagliptin on intact and total GLP-1 and GIP levels in insulin-dependent type 2 diabetic patients with and without moderate renal impairment.. <b>2022</b> ,                 |   |
| 499 | LRG1: an emerging player in disease pathogenesis.. <b>2022</b> , 29, 6   | 5 |
| 498 | Prediction of diabetic kidney disease with machine learning algorithms, upon the initial diagnosis of type 2 diabetes mellitus.. <b>2022</b> , 10,   | 7 |
| 497 | Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management.. <b>2022</b> , 13, 25   | 3 |
| 496 | Impact of random variation in albuminuria and eGFR on patient enrolment and duration of clinical trials in nephrology.. <b>2022</b> ,  | 0 |
| 495 | JMJD1A/NR4A1 Signaling Regulates the Procession of Renal Tubular Epithelial Interstitial Fibrosis Induced by AGEs in HK-2.. <b>2021</b> , 8, 807694  | 1 |
| 494 | Influence Engulfment Cell Motility-1 (ELMO-1) Protein and Matrix Metalloproteases-9 (MMP-9) in Diabetic Nephropathy Patients.  |   |
| 493 | Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.. <b>2022</b> , 22, 39   | 5 |

|     |   |   |
|-----|---|---|
| 492 | The role of oxidative stress markers in Indonesian chronic kidney disease patients: a cross sectional study. 11, 132  | 0 |
| 491 | Hypoxia preconditioning increases the ability of healthy but not diabetic rat-derived adipose stromal/stem cells (ASC) to improve histological lesions of streptozotocin-induced diabetic nephropathy.. 2021, 230, 153756 | 0 |
| 490 | Effects of L-Carnitine Treatment on Kidney Mitochondria and Macrophages in Mice with Diabetic Nephropathy.. 2022,   | 1 |
| 489 | Long non-coding RNA TUG1 sponges microRNA-9 to protect podocytes from high glucose-induced apoptosis and mitochondrial dysfunction via SIRT1 upregulation.. 2022, 23, 236   | 0 |
| 488 | Chronic kidney disease and renal replacement therapy: an overview for the advanced clinical practitioner.. 2022, 31, 124-134  | 0 |
| 487 | The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF).. 2021,  | 0 |
| 486 | The effect of allopurinol on renal outcomes in patients with diabetic kidney disease: A systematic review and meta-analysis.. 2022,   | 0 |
| 485 | TFPI2 suppresses the interaction of TGF- $\beta$ pathway regulators to promote endothelial-mesenchymal transition in diabetic nephropathy.. 2022, 101725  | 1 |
| 484 | Hydrogen Sulfide and the Kidney: Physiological Roles, Contribution to Pathophysiology, and Therapeutic Potential.. 2021,  | 1 |
| 483 | Multi-scalar data integration links glomerular angiotensin-2 signaling pathway activation with progression of diabetic kidney disease.  |   |
| 482 | Indications and considerations for kidney biopsy: an overview of clinical considerations for the non-specialist.. 2021,   | 0 |
| 481 | Can Newer Anti-Diabetic Therapies Delay the Development of Diabetic Nephropathy?. 2021, 13, 341-351   |   |
| 480 | Dioscin relieves diabetic nephropathy suppressing oxidative stress and apoptosis, and improving mitochondrial quality and quantity control.. 2022, 13, 3660-3673  | 2 |
| 479 | OUP accepted manuscript.  | 1 |
| 478 | Updates in Nephrology for the Hospitalist. 2022, 41-57  |   |
| 477 | Diabetic Nephropathy. 2022, 397-409   |   |
| 476 | Medication Adherence, Complementary Medicine Usage and Progression of Diabetic Chronic Kidney Disease in Thais.. 2022, 16, 467-477  |   |
| 475 | Blood DNA Methylation Predicts Diabetic Kidney Disease Progression in High Fat Diet-Fed Mice.. 2022, 14,  | 1 |



|     |   |   |
|-----|---|---|
| 474 | Hip Fracture Risk According to Diabetic Kidney Disease Phenotype in a Korean Population.. <b>2022</b> , 37, 148-158   | 0 |
| 473 | 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.. <b>2022</b> ,  | 0 |
| 472 | Multiparametric magnetic resonance imaging allows non-invasive functional and structural evaluation of diabetic kidney disease.   | 0 |
| 471 | Asparaginyl endopeptidase protects against podocyte injury in diabetic nephropathy through cleaving cofilin-1.. <b>2022</b> , 13, 184   | 1 |
| 470 | Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases.  |   |
| 469 | Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury.. <b>2022</b> , 1  | 0 |
| 468 | Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease.. <b>2022</b> , 46, 181-197   | 3 |
| 467 | Ferroptosis as a Novel Therapeutic Target for Diabetes and Its Complications.. <b>2022</b> , 13, 853822   | 1 |
| 466 | Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis.. <b>2022</b> , 17, e0265642  | 2 |
| 465 | Podocyte Injury in Diabetic Kidney Disease: A Focus on Mitochondrial Dysfunction.. <b>2022</b> , 10, 832887   | 1 |
| 464 | Effectiveness of Remotely Delivered Interventions to Simultaneously Optimize Management of Hypertension, Hyperglycemia and Dyslipidemia in People With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. <b>2022</b> , 13, 848695 | 0 |
| 463 | Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.. <b>2022</b> , 21, 47  | 1 |
| 462 | Potential Therapeutic Targets of Rehmannia Formulations on Diabetic Nephropathy: A Comparative Network Pharmacology Analysis.. <b>2022</b> , 13, 794139   | 0 |
| 461 | GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions.. <b>2022</b> , 41, 136-149  | 0 |
| 460 | Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease Inhibition of NLRP3 Inflammasome-Mediated Podocyte Pyroptosis.. <b>2022</b> , 13, 790937  | 0 |
| 459 | Translational Approach to the Protective Effect of Bilirubin in Diabetic Kidney Disease.. <b>2022</b> , 10,   | 0 |
| 458 | Transcriptome expression profiles associated with diabetic nephropathy development.. <b>2022</b> , 1  | 0 |
| 457 | Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.. <b>2022</b> ,   | 0 |

- 456 Antioxidant for treatment of diabetic complications: A meta-analysis and systematic review.. **2022**, e23038 1
- 455 Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice.. **2022**, 13, 778776 1
- 454 Fecal Microbiota Transplant in a Pre-Clinical Model of Type 2 Diabetes Mellitus, Obesity and Diabetic Kidney Disease.. **2022**, 23, 1
- 453 Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3.. **2022**,
- 452 Development of clinical prediction models for renal and cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease using time-varying predictors.. **2022**, 108180
- 451 Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Recurrent Peritonitis in Peritoneal Dialysis Patients?. **2022**, 11, 0
- 450 Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: A dose-response meta-analysis.. **2022**, 0
- 449 Reduced Glomerular Filtration in Diabetes is Attributable to Loss of Density and Increased Resistance of Glomerular Endothelial Cell Fenestrations.. **2022**, 0
- 448 Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice.. **2021**, 12, 777395 0
- 447 Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study.. **2022**, 1-31 1
- 446 Glomerular hyperfiltration.. **2022**, 2
- 445 Medications and the Kidney. **2022**, 7, 215-228
- 444 The role of CDH2 and MCP-1 mRNAs of blood extracellular vesicles in predicting early-stage diabetic nephropathy.. **2022**, 17, e0265619
- 443 Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. **2022**, 21, 50 1
- 442 Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review.. **2022**, 1
- 441 Plasma or Urine Neutrophil Gelatinase-Associated Lipocalin (NGAL): Which Is Better at Detecting Chronic Kidney Damage in Type 2 Diabetes?. **2022**, 3, 175-186 3
- 440 Supplementation of conventional anti-diabetic therapy with alpha-lipoic acid prevents early development and progression of diabetic nephropathy.. **2022**, 149, 112818 0
- 439 Cyclocarya paliurus triterpenoids attenuate glomerular endothelial injury in the diabetic rats via ROCK pathway.. **2022**, 291, 115127 0

- 438 mitigates microvascular complications of type 2 diabetes mellitus: the involvement of oxidative stress and aldose reductase.. **2021**, 37, 69-80
- 437 SGLT2i agonist and GLP-1 receptor COMBination therapy in type 2 diabetes: Protocol for a KIDney endpoints real world study-[COMBi-KID Study] (Preprint).
- 436 MicroRNA 1228 Mediates the Viability of High Glucose-Cultured Renal Tubule Cells through Targeting Thrombospondin 2 and PI3K/AKT Signaling Pathway. **2021**, 1-12 0
- 435 Mitochondrial dynamics and diabetic kidney disease: Missing pieces for the puzzle of therapeutic approaches. **2021**, 1
- 434 Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 6.9 3
- 433 NAD metabolism modulates mitochondrial function and inflammation and prevents progression of diabetic kidney disease.
- 432 Discovery of caffeoylisocitric acid as a Keap1-dependent Nrf2 activator and its effects in mesangial cells under high glucose.. **2022**, 37, 178-188 0
- 431 Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist's point of view.. **2021**, 3
- 430 Significance of serum miR-29a in the occurrence and progression of diabetic nephropathy: A cross-sectional study.. **2021**, e24210 1
- 429 Kidney Failure Risk Equation and Cost of Care in Patients with Chronic Kidney Disease.. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 6.9 1
- 428 Autocrine Exosomal Fibulin-1 as a Target of MiR-1269b Induces Epithelial-Mesenchymal Transition in Proximal Tubule in Diabetic Nephropathy.. **2021**, 9, 789716 0
- 427 Workplace Outreach Program Improves Management of Chronic Kidney Disease.. **2021**,
- 426 Sex-specific Effects of SGLT2 Inhibition in a Kidney with Reduced Nephron Number: Modeling and Analysis.
- 425 Diabetic kidney disease-predisposing proinflammatory and profibrotic genes identified by weighted gene co-expression network analysis (WGCNA).. **2021**, 3
- 424 Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium.. **2021**, 1-10
- 423 Herbal Drugs used in the Management of Diabetic Nephropathy. **2022**, 54-60
- 422 Identification of histopathological and clinical spectrum of diabetic kidney disease based on an unsupervised hierarchical clustering analysis of elderly autopsy specimens.. **2022**,
- 421 Critical shear stress of red blood cells as a novel integrated biomarker for screening chronic kidney diseases in cases of type 2 diabetes.. **2022**, 0

|     |  |   |
|-----|--|---|
| 420 | Fibroblast Growth Factor 21 Levels Exhibit the Association With Renal Outcomes in Subjects With Type 2 Diabetes Mellitus.. <b>2022</b> , 13, 846018                        | 0 |
| 419 | Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology.. <b>2022</b> ,                 | 0 |
| 418 | A vegetable oil blend administration mitigates the hyperglycemia-induced redox imbalance, renal histopathology, and function in diabetic nephropathy. <b>2022</b> , 102018 | 0 |
| 417 | Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression - real-world clinical practice.  | 0 |
| 416 | Cognitive disorder and dementia in type 2 diabetes mellitus.. <b>2022</b> , 13, 319-337  | 2 |
| 415 | Long Non-Coding RNAs in the Pathogenesis of Diabetic Kidney Disease.. <b>2022</b> , 10, 845371   | 1 |
| 414 | New Approaches to Diabetic Nephropathy from Bed to Bench.. <b>2022</b> , 10,   | 1 |
| 413 | Data_Sheet_1.docx. <b>2019</b> ,   |   |
| 412 | Table_1.docx. <b>2019</b> ,  |   |
| 411 | DataSheet_1.docx. <b>2020</b> ,  |   |
| 410 | table1.docx. <b>2020</b> ,   |   |
| 409 | DataSheet_1.doc. <b>2020</b> ,   |   |
| 408 | Presentation_1.pptx. <b>2019</b> ,   |   |
| 407 | A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes.. <b>2022</b> , 9, 20543581221081207                     | 0 |
| 406 | Urinary Interleukins and Kidney Damage in Diabetes. <b>2022</b> , 1-18   |   |
| 405 | SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist. <b>2022</b> , 2,   | 1 |
| 404 | Mapping research in diabetes complications; A scoping review. 1  |   |
| 403 | Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.. <b>2022</b> ,                 | 1 |

|     |   |   |
|-----|---|---|
| 402 | Recent advances in the biosynthesis, structure-activity relationships, formulations, pharmacology, and clinical trials of fisetin. <b>2022</b> , 3,   | 3 |
| 401 | Diabetic kidney disease versus non-diabetic kidney disease in type 2 diabetic patients on dialysis: An observational cohort.. <b>2022</b> , e00281  |   |
| 400 | Characteristics of Serum Metabolites and Gut Microbiota in Diabetic Kidney Disease.. <b>2022</b> , 13, 872988   | 0 |
| 399 | Flower Aqueous Extract Protects against Oxidative Stress-Induced Nephropathy in a Rat Model of Type 2 Diabetes.. <b>2022</b> , 2022, 2814196  | 1 |
| 398 | Outcomes of Diabetic Ketoacidosis in Adults With End-Stage Kidney Disease: Retrospective Study Based on a National Database. <b>2022</b> ,  |   |
| 397 | Serum Metabolomics Benefits Discrimination Kidney Disease Development in Type 2 Diabetes Patients. <b>2022</b> , 9,   | 0 |
| 396 | Intrarenal arterial administration of human umbilical cord-derived mesenchymal stem cells effectively preserved the residual renal function of diabetic kidney disease in rat.. <b>2022</b> , 13, 186 | 1 |
| 395 | Heterogeneity in the association between prediabetes categories and reduction on glomerular filtration rate in a 5-year follow-up.. <b>2022</b> , 12, 7373  | 0 |
| 394 | Nanoarchitected superparamagnetic iron oxide-doped mesoporous carbon nanozymes for glucose sensing. <b>2022</b> , 366, 131980   | 2 |
| 393 | The role of glutathione transferase polymorphisms in the development of diabetic nephropathy. <b>2021</b> , 12, 193-203   |   |
| 392 | Notch3-Mediated mTOR Signaling Pathway Is Involved in High Glucose-Induced Autophagy in Bovine Kidney Epithelial Cells. <b>2022</b> , 27, 3121  | 0 |
| 391 | Mechanism of Cordyceps sinensis and its Extracts in the Treatment of Diabetic Kidney Disease: A Review. <b>2022</b> , 13,   | 0 |
| 390 | Association of impaired kidney function with mortality in rural Uganda: results of a general population cohort study.. <b>2022</b> , 12, e051267  | 0 |
| 389 | Etiopathogenesis of kidney disease in minority populations and an updated special focus on treatment in diabetes and hypertension.. <b>2022</b> ,   |   |
| 388 | Usefulness of urinary biomarkers to estimate the interstitial fibrosis surface in diabetic nephropathy with normal kidney function.. <b>2022</b> ,  | 0 |
| 387 | Epigenetics and 5-Hydroxymethylcytosines as a Biomarker in Type 2 Diabetes. <b>2022</b> , 1-18  |   |
| 386 | Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. <b>2022</b> , 13,  | 2 |
| 385 | Integrated Bioinformatics and Clinical Correlation Analysis of Key Genes, Pathways, and Potential Therapeutic Agents Related to Diabetic Nephropathy. <b>2022</b> , 2022, 1-13                        | 0 |

- 384 Association of Dietary Fish and n-3 Unsaturated Fatty Acid Consumption with Diabetic Nephropathy from a District Hospital in Northern Taiwan. **2022**, 14, 2148 0
- 383 Combined Single-Cell RNA-Seq and Spatial Transcriptomics Reveal an Atlas of Human Diabetic Kidney Disease. 0
- 382 Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF/Akt/ERK pathways. **2022**, 28, 2
- 381 Proteomics and Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology. **2022**, 23, 5779 1
- 380 An update on the approaches of avoidance of propagation of chronic kidney disease resulting in reversal or possible need or avoidance of kidney transplantation - a systematic review. **2022**, 6, 040-057
- 379 Intensive blood pressure control and cognitive impairment in chronic kidney disease: The jury is still out. **2022**, 0
- 378 Antioxidative Stress and Anti-Inflammatory Activity of Fucoidan Nanoparticles against Nephropathy of Streptozotocin-Induced Diabetes in Rats. **2022**, 2022, 1-10 2
- 377 The Roles of Fatty Acids and Apolipoproteins in the Kidneys. **2022**, 12, 462 0
- 376 Emerging Role of Epitranscriptomics in Diabetes Mellitus and Its Complications. **2022**, 13, 1
- 375 PodoCount: A Robust, Fully Automated, Whole-Slide Podocyte Quantification Tool. **2022**, 7, 1377-1392 0
- 374 Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease. **2022**, 4
- 373 Six-Month Periodic Fasting in Patients With Type 2 Diabetes and Diabetic Nephropathy: A Proof-of-Concept Study. 3
- 372 Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. *Clinical Journal of the American Society of Nephrology: CJASN*, CJN.02980322 6.9 1
- 371 Long non coding RNA L13Rik promotes high glucose-induced mesangial cell injury by regulating miR-2861/CDKN1B axis. 1
- 370 Research Progress of Intestinal Flora and Type 2 Diabetes Mellitus Microangiopathy. **2022**, 12, 5299-5303
- 369 Sex-Based Differences in Risk Factors and Complications of Chronic Kidney Disease. **2022**, 42, 153-169 1
- 368 Epigallocatechin Gallate Induces the Demethylation of Actinin Alpha 4 to Inhibit Diabetic Nephropathy Renal Fibrosis via the NF-KB Signaling Pathway In Vitro. **2022**, 20, 155932582211057 1
- 367 Potential Role of N-Cadherin in Diagnosis and Prognosis of Diabetic Nephropathy. 13,

|     |   |   |
|-----|---|---|
| 366 | Increased glucocorticoid metabolism in diabetic kidney disease. <b>2022</b> , 17, e0269920  | 0 |
| 365 | The Specific Alteration of Gut Microbiota in Diabetic Kidney Diseases—A Systematic Review and Meta-Analysis. 13,  | 2 |
| 364 | Procyanidin B2 suppresses hyperglycemia-induced renal mesangial cell dysfunction by modulating CAV-1-dependent signaling. <b>2022</b> , 24,   | 1 |
| 363 | Ombuin ameliorates diabetic nephropathy in rats by anti-inflammation and antifibrosis involving Notch 1 and PPAR $\beta$ signaling pathways.  | 0 |
| 362 | Design of the COMbination effect of FInerenone and EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE).                       | 1 |
| 361 | Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.   | 0 |
| 360 | Gut Mycobiome in Patients With Chronic Kidney Disease Was Altered and Associated With Immunological Profiles. 13,   | 0 |
| 359 | Metabolic Dysfunction in the Regulation of the NLRP3 Inflammasome Activation: A Potential Target for Diabetic Nephropathy. <b>2022</b> , 2022, 1-14   | 0 |
| 358 | Ldlr-Deficient Mice with an Atherosclerosis-Resistant Background Develop Severe Hyperglycemia and Type 2 Diabetes on a Western-Type Diet. <b>2022</b> , 10, 1429                                  | 0 |
| 357 | Effect of Glucagon-like Peptide 1 Receptor Agonists on the Renal Protection in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <b>2022</b> , 101366                         | 0 |
| 356 | Sirtuin Family and Diabetic Kidney Disease. 13,   | 0 |
| 355 | Targeting inflammation for the treatment of Diabetic Kidney Disease: a five-compartment mechanistic model. <b>2022</b> , 23,  | 2 |
| 354 | An Evaluation of Alternative Technology-Supported Counseling Approaches to Promote Multiple Lifestyle Behavior Changes in Patients with Type 2 Diabetes and Chronic Kidney Disease. <b>2022</b> , | 0 |
| 353 | Protective effect of the tunneling nanotube-TNFAIP2/M-sec system on podocyte autophagy in diabetic nephropathy. 1-20  | 0 |
| 352 | 12(S)-hydroxyeicosatetraenoic acid is significantly increased in diabetic kidney disease and associated with renal function decline.  | 0 |
| 351 | Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system.   | 0 |
| 350 | The Preventive Effects of Fermented and Germinated Foxtail Millet Whole Grain on Kidney Damage in a Diabetic Mouse Model. 9,  | 0 |
| 349 | Demethylzeylasteral reduces the level of proteinuria in diabetic nephropathy: Screening of network pharmacology and verification by animal experiment. <b>2022</b> , 10,                          | 0 |

- 348 LncRNA MALAT1 Aggravates Renal Tubular Injury via Activating LIN28A and the Nox4/AMPK/mTOR Signaling Axis in Diabetic Nephropathy. 13, 0
- 347 Low Serum Dehydroepiandrosterone Is Associated With Diabetic Kidney Disease in Men With Type 2 Diabetes Mellitus. 13, 1
- 346 Effects of Qidantang Granule on early stage of diabetic kidney disease in rats. **2022**, 14, 4888-4896 0
- 345 The Burden of Diabetes-Related Chronic Kidney Disease in China From 1990 to 2019. 13, 0
- 344 Diabetic nephropathy: Clinical presentation, course, and novel treatment possibilities. **2022**, 1-1
- 343 Pathogenic Role of MicroRNA Dysregulation in Podocytopathies. 13, 0
- 342 The analysis of risk factors for diabetic kidney disease progression: a single-centre and cross-sectional experiment in Shanghai. **2022**, 12, e060238 0
- 341 Comparing Multiple Linear Regression and Machine Learning in Predicting Diabetic Urine Albumin:creatinine Ratio in a 4-Year Follow-Up Study. **2022**, 11, 3661 1
- 340 Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease. **2022**, 0
- 339 Predictive significance of joint plasma fibrinogen and urinary alpha-1 microglobulin-creatinine ratio in patients with diabetic kidney disease. **2022**, 17, e0271181
- 338 Mechanism of Cornus Officinalis in Treating Diabetic Kidney Disease Based on Network Pharmacology. **2022**, 2022, 1-14
- 337 The Complement System in Metabolic-Associated Kidney Diseases. 13, 0
- 336 Effective Dose/Duration of Natural Flavonoid Quercetin for Treatment of Diabetic Nephropathy: A Systematic Review and Meta-Analysis of Rodent Data. **2022**, 154348 1
- 335 TFP5-Mediated CDK5 Activity Inhibition Improves Diabetic Nephropathy via NGF/Sirt1 Regulating Axis. 10, 0
- 334 Identification of key genes and biological regulatory mechanisms in diabetic nephropathy: Meta-analysis of gene expression datasets. **2022**, 0
- 333 Lipocalin-Type Prostaglandin D2 Synthase Protein- A Central Player in Metabolism. 0
- 332 Depression is a main determinant of health-related quality of life in patients with diabetic kidney disease. **2022**, 12, 0
- 331 Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. 1-13 0



- 330 Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus. **2022**, 22,
- 329 Inhibition of HDAC6 With CAY10603 Ameliorates Diabetic Kidney Disease by Suppressing NLRP3 Inflammasome. 13,
- 328 Time restricted feeding decreases renal innate immune cells and blood pressure in hypertensive mice. Publish Ahead of Print, 1
- 327 The Interplay of NEAT1 and miR-339-5p Influences on Mesangial Gene Expression and Function in Various Diabetic-Associated Injury Models. **2022**, 8, 52 0
- 326 Epigallocatechin-3-gallate ameliorates renal endoplasmic reticulum stress-mediated inflammation in type 2 diabetic rats. 153537022211064 0
- 325 Upregulation of VSIG4 in Type 2 Diabetic Kidney Disease. **2022**, 12, 1031
- 324 Serum Adiponectin Level in Different Stages of Type 2 Diabetic Kidney Disease: A Meta-Analysis. **2022**, 2022, 1-11
- 323 Activation of renal CSE/H2S pathway by alpha-lipoic acid protects against histological and functional changes in the diabetic kidney. **2022**, 153, 113386 1
- 322 Compromised glycolysis contributes to foot process fusion of podocytes in diabetic kidney disease: Role of ornithine catabolism. **2022**, 134, 155245 0
- 321 Glycated Hemoglobin Levels and Risk of All-cause and Cause-specific Mortality in Hemodialysis Patients with Diabetes. **2022**, 110016
- 320 TMBIM6 promotes diabetic tubular epithelial cell survival and albumin endocytosis by inhibiting the endoplasmic reticulum stress sensor, IRE1 $\beta$
- 319 Reprogramming Metabolism of Macrophages as a Target for Kidney Dysfunction Treatment in Autoimmune Diseases. **2022**, 23, 8024
- 318 Impact of SARS-CoV-2 pandemic on food security in patients with chronic kidney disease. **2022**, 0
- 317 GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease. **2022**, 2, 386-398
- 316 Weight change and fracture risk in patients with diabetic kidney disease: A nationwide population-based study. 9,
- 315 The Role of Platelets in Diabetic Kidney Disease. **2022**, 23, 8270
- 314 Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria. **2022**, 10, e002806 0
- 313 Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study. **2022**, 14,

- 312 Ferulic acid ameliorates renal injury via improving autophagy to inhibit inflammation in diabetic nephropathy mice. **2022**, 153, 113424 0
- 311 Editorial: Advancements in the management of kidney disease and electrolyte derangements. **2022**, 31, 395-398
- 310 Crataegus oxyacantha Extract Mitigates Diabetic Nephropathy via Oxidative Stress Regulation in Streptozotocin-Induced Zebrafish Model. **2022**, 18, 1252-1260
- 309 Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives. Volume 18, 753-760 0
- 308 Predicting diabetic nephropathy in type 2 diabetic patients using machine learning algorithms. 0
- 307 Antioxidant Silk Fibroin Composite Hydrogel for Rapid Healing of Diabetic Wound. 2200097 1
- 306 Effect of BBT-877, a novel inhibitor of ATX, on a mouse model of type 1 diabetic nephropathy. 0
- 305 The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—review of the current literature. **2022**, 20, 1
- 304 Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease. **2022**, 17, e0273004 0
- 303 Aerobic exercise training alleviates renal injury in db/db mice through inhibiting Nox4-mediated NLRP3 inflammasome activation. **2022**, 111934 0
- 302 Managing thrombotic risk in patients with diabetes. **2022**, 21, 0
- 301 ANRIL regulates multiple molecules of pathogenetic significance in diabetic nephropathy. **2022**, 17, e0270287
- 300 Identification of novel key genes and potential candidate small molecule drugs in diabetic kidney disease using comprehensive bioinformatics analysis. 13, 0
- 299 Mass spectrometry-based N-glycosylation analysis in kidney disease. 9, 0
- 298 The combination of high glucose and LPS induces autophagy in bovine kidney epithelial cells via the Notch3/mTOR signaling pathway. **2022**, 18, 0
- 297 Prediction of diabetic kidney disease risk using machine learning models: a population-based cohort study of Asian adults. 0
- 296 WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. **2022**, 8
- 295 Pathophysiology of mesangial expansion in diabetic nephropathy: mesangial structure, glomerular biomechanics, and biochemical signaling and regulation. **2022**, 16, 1

- 294 *Sigesbeckia orientalis* Extract Ameliorates the Experimental Diabetic Nephropathy by Downregulating the Inflammatory and Oxidative Stress Signaling Pathways. **2022**, 2022, 1-13
- 293 Network pharmacology and molecular docking technology-based predictive study of the active ingredients and potential targets of rhubarb for the treatment of diabetic nephropathy. **2022**, 22, 0
- 292 Up-Date on Diabetic Nephropathy. **2022**, 12, 1202 2
- 291 Global mortality of diabetic foot ulcer: a systematic review and meta-analysis of observational studies. 0
- 290 The Protective Effects of Neurotrophins and MicroRNA in Diabetic Retinopathy, Nephropathy and Heart Failure via Regulating Endothelial Function. **2022**, 12, 1113 0
- 289 When to Suspect Non-diabetic Kidney Disease in a Diabetic Patient?. **2022**,
- 288 Cyproheptadine, a SET7/9 inhibitor, reduces hyperglycaemia-induced ER stress alleviating inflammation and fibrosis in renal tubular epithelial cells. 1-9 0
- 287 Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. 0
- 286 Can the Artificial Intelligence System for Urine Microalbuminuria Detection Monitor the Progression of Diabetic Kidney Disease in the Clinical Laboratory?.
- 285 Investigation on maintenance hemodialysis patients with mineral and bone disorder in Anhui province, China.
- 284 Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. 1
- 283 Chrysin improves diabetic nephropathy by regulating the AMPK -mediated lipid metabolism in HFD / STZ -induced DN mice.
- 282 Sappanone a prevents diabetic kidney disease by inhibiting kidney inflammation and fibrosis via the NF- $\kappa$ B signaling pathway. 13,
- 281 New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation. **2022**, 14, 1
- 280 Emerging role of neutrophil extracellular traps in the complications of diabetes mellitus. 9, 0
- 279 MD Simulation Studies for Selective Phytochemicals as Potential Inhibitors against Major Biological Targets of Diabetic Nephropathy. **2022**, 27, 4980
- 278 Identification and validation of key biomarkers for the early diagnosis of diabetic kidney disease. 13, 0
- 277 Ocular findings, surgery details and outcomes in proliferative diabetic retinopathy patients with chronic kidney disease.

- 276 Interaction between Plasma Metabolomics and Intestinal Microbiome in db/db Mouse, an Animal Model for Study of Type 2 Diabetes and Diabetic Kidney Disease. **2022**, 12, 775 ○
- 275 Adropin Carried by Reactive Oxygen Species-Responsive Nanocapsules Ameliorates Renal Lipid Toxicity in Diabetic Mice. **2022**, 14, 37330-37344 ○
- 274 Exploring the pathogenesis of diabetic kidney disease by microarray data analysis. 13, ○
- 273 Association between central obesity and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching. **2022**, 12, ○
- 272 Increased thromboxane/prostaglandin receptors contribute to high glucose-induced podocyte injury and mitochondrial fission through ROCK1-Drp1 signaling. **2022**, 151, 106281 ○
- 271 Assessment of microvascular function using a novel technique Flow Mediated Skin Fluorescence (FMSF) in patients with diabetic kidney disease: A preliminary study. **2022**, 144, 104417 1
- 270 A bibliometric analysis of RNA methylation in diabetes mellitus and its complications from 2002 to 2022. 13, ○
- 269 Prognostic Nutritional Index as a Predictor of Diabetic Nephropathy Progression. **2022**, 14, 3634 ○
- 268 Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes. ○
- 267 Tripterygium glycoside tablet attenuates renal function impairment in diabetic nephropathy mice by regulating triglyceride metabolism. **2022**, 221, 115028 1
- 266 Circular RNAs in Diabetic Nephropathy: Updates and Perspectives. **2022**, 13, 1365 ○
- 265 Research Progress in the Application of Finerenone in Patients with DKD. **2022**, 12, 8325-8329 ○
- 264 Insights from Proteomics in Kidney Disease Diagnosis and Various In Vitro and In Vivo Experimental Models. **2022**, 27-69 ○
- 263 Approach to correction of apoptotic disorders in children with early diabetic nephropathy ?. **2022**, 12, 104-109 ○
- 262 EARLY MARKERS OF DIABETIC NEPHROPATHY IN CHILDREN WITH TYPE 1 DIABETES MELLITUS. **2022**, 18, 013 ○
- 261 Prooxidant-antioxidant balance ¶relationship with kidney damage in type 2 diabetes mellitus. **2022**, 91, 72-82 ○
- 260 Circ\_0060077 Knockdown Alleviates High-Glucose-Induced Cell Apoptosis, Oxidative Stress, Inflammation and Fibrosis in HK-2 Cells via miR-145-5p/VASN Pathway. **2022**, 45, 1911-1923 ○
- 259 Gene-Based Network Analysis Reveals Prognostic Biomarkers Implicated in Diabetic Tubulointerstitial Injury. **2022**, 2022, 1-15 ○

|     |  |   |
|-----|--|---|
| 258 | Exosomes derived from mesenchymal stem cells attenuate diabetic kidney disease by inhibiting cell apoptosis and epithelial-to-mesenchymal transition via miR-424-5p. <b>2022</b> , 36, | 1 |
| 257 | Effect of Influenza Vaccination on the Reduction of the Incidence of Chronic Kidney Disease and Dialysis in Patients with Type 2 Diabetes Mellitus. <b>2022</b> , 11, 4520             | 0 |
| 256 | Impact of Diabetic Nephropathy on Pulmonary Function and Clinical Outcomes. <b>2022</b> , 2022, 1-11   | 0 |
| 255 | Immunoglobulin A Nephropathy in a SARS-CoV-2-Positive Patient With Coexistent Metabolic Syndrome. <b>2022</b> ,  | 0 |
| 254 | Integrin $\alpha$ /Cell Surface GRP78 Complex Regulates TGF $\beta$ and Its Profibrotic Effects in Response to High Glucose. <b>2022</b> , 10, 2247                                    | 0 |
| 253 | Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes. <b>2022</b> ,  | 0 |
| 252 | Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease. 13,  | 0 |
| 251 | Analysis of the Association between Metabolic Syndrome and Renal Function in Middle-Aged Patients with Diabetes. <b>2022</b> , 19, 11832   | 0 |
| 250 | Salivary microbiome in chronic kidney disease: what is its connection to diabetes, hypertension, and immunity?. <b>2022</b> , 20,  | 1 |
| 249 | Transcriptional sequencing analysis reveals the potential use of deer antler for Bonifying the kidney and strengthening bone <b>2022</b> , 17,   | 0 |
| 248 | Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis.  | 0 |
| 247 | O-GlcNAcylation in Renal (Patho)Physiology. <b>2022</b> , 23, 11260  | 1 |
| 246 | Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. <b>2022</b> , 23, 10882   | 0 |
| 245 | Circulating expression and clinical significance of LncRNA ANRIL in diabetic kidney disease.   | 1 |
| 244 | Systematic Review of the Role of Alpha-Protein Kinase 1 in Cancer and Cancer-Related Inflammatory Diseases. <b>2022</b> , 14, 4390   | 0 |
| 243 | SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway. 13,                                      | 2 |
| 242 | The IRE1 $\beta$ pathway in glomerular diseases: The unfolded protein response and beyond. 2,  | 0 |
| 241 | Genetic deletion and pharmacologic inhibition of FcER1 reduces renal injury in mouse models of diabetic nephropathy.   | 0 |

- 240 Diagnosis of type 2 Diabetes Mellitus (T2DM) using Paired microRNAs. ○
- 239 Pulse pressure and the risk of renal hyperfiltration in young adults: Results from Korea National Health and Nutrition Examination Survey (2010-2019). 9, ○
- 238 Urinary Interleukins and Kidney Damage in Diabetes. **2023**, 261-278 ○
- 237 Continuous glucose monitoring in diabetes patients with chronic kidney disease on dialysis: a meta-analysis. **2022**, 47, ○
- 236 Genetically predicted body fat mass and distribution with diabetic kidney disease: A two-sample Mendelian randomization study. 13, ○
- 235 Epigenetics and 5-Hydroxymethylcytosines as a Biomarker in Type 2 Diabetes. **2023**, 541-558 ○
- 234 Time to doubling of serum creatinine in patients with diabetes in Ethiopian University Hospital: Retrospective follow-up study. **2022**, 17, e0274495 ○
- 233 Development and validation of a risk score for diabetic kidney disease prediction in type 2 diabetes patients: a machine learning approach. ○
- 232 Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline. Volume 15, 2847-2856 ○
- 231 The clinical implications of pre-liver transplant diabetes on post-liver transplant outcomes in patients with NASH: analysis of the UNOS database. ○
- 230 Dynein-mediated trafficking and degradation of nephrin in diabetic podocytopathy. ○
- 229 Analysis of the Renal Protection and Antioxidative Stress Effects of Panax notoginseng Saponins in Diabetic Nephropathy Mice. **2022**, 2022, 1-9 ○
- 228 Frailty, physical performance and mortality in older patients with and without diabetic kidney disease: a longitudinal cohort study. ○
- 227 Proteomic profiling and correlations with clinical features reveal biomarkers indicative of diabetic retinopathy with diabetic kidney disease. 13, ○
- 226 Cathelicidin as a marker for subclinical cardiac changes and microvascular complications in children and adolescents with type 1 diabetes. **2022**, ○
- 225 Correlation analysis between Tervaert glomerular classification and clinical indicators in patients with type 2 diabetic nephropathy. **2022**, 2, 32-39 ○
- 224 The application effect of the trans-theoretical model of behavior change in diabetic kidney disease patients treated with maintenance hemodialysis. **2022**, 2, 24-30 ○
- 223 Acute kidney injury and diabetic kidney disease in children with acute complications of diabetes. ○

- 222 The Effects of *Ophiocordyceps sinensis* Combined with ACEI/ARB on Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. **2022**, 154531 ○
- 221 NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells. **2022**, 121142 ○
- 220 Blocking connexin 43 hemichannel-mediated ATP release reduces communication within and between tubular epithelial cells and medullary fibroblasts in a model of diabetic nephropathy. 1
- 219 Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. **2022**, 10, 2586 ○
- 218 Ocular findings, surgery details and outcomes in proliferative diabetic retinopathy patients with chronic kidney disease. **2022**, 17, e0273133 ○
- 217 Discovering hub genes involved in the pathophysiological impact of COVID-19 on diabetes kidney disease by differential gene expression and interactome analysis. ○
- 216 GTS-21, a selective alpha7 nicotinic acetylcholine receptor agonist, ameliorates diabetic nephropathy in *Lepr* db/db mice. ○
- 215 Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with diabetic kidney disease in patients with type 2 diabetes. ○
- 214 The Potential Applications of Raman Spectroscopy in Kidney Diseases. **2022**, 12, 1644 ○
- 213 Mechanism of *Tripterygium wilfordii* Hook.F.- *Trichosanthes kirilowii* Maxim decoction in treatment of diabetic kidney disease based on network pharmacology and molecular docking. 13, ○
- 212 New strategies to improve clinical outcomes for diabetic kidney disease. **2022**, 20, ○
- 211 Type 2 diabetes albuminuric and non-albuminuric phenotypes have different morphological and functional ultrasound features of diabetic kidney disease. ○
- 210 Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials. 13, ○
- 209 Advancing a causal role of type 2 diabetes and its components in developing macro- and microvascular complications via genetic studies. 2
- 208 Polymorphisms in glucose homeostasis genes are associated with cardiovascular and renal parameters in patients with diabetic nephropathy. **2022**, 54, 3039-3051 ○
- 207 The Effect of Allograft Inflammatory Factor-1 on Inflammation, Oxidative Stress, and Autophagy via miR-34a/ATG4B Pathway in Diabetic Kidney Disease. **2022**, 2022, 1-22 ○
- 206 KITLG Promotes Glomerular Endothelial Cell Injury in Diabetic Nephropathy by an Autocrine Effect. **2022**, 23, 11723 ○
- 205 Metabolomic Signature of Diabetic Kidney Disease in Cerebrospinal Fluid and Plasma of Patients with Type 2 Diabetes Using Liquid Chromatography-Mass Spectrometry. **2022**, 12, 2626 ○

|     |   |   |
|-----|---|---|
| 204 | Resistant Starch as a Dietary Intervention to Limit the Progression of Diabetic Kidney Disease. <b>2022</b> , 14, 4547  | 1 |
| 203 | Nidogen-1 could play a role in diabetic kidney disease development in type 2 diabetes: a genome-wide association meta-analysis. <b>2022</b> , 16,                                   | 0 |
| 202 | NLRP3-mediated pyroptosis in diabetic nephropathy. 13,  | 0 |
| 201 | The role of small extracellular vesicle non-coding RNAs in kidney diseases. 13,   | 0 |
| 200 | Patient and health care provider knowledge of diabetes and diabetic microvascular complications: a comprehensive literature review.   | 0 |
| 199 | Youth versus adult-onset type 2 diabetic kidney disease: Insights into currently known structural differences and the potential underlying mechanisms. <b>2022</b> , 136, 1471-1483 | 0 |
| 198 | Dietary restriction and medical therapy drive PPAR $\beta$ -regulated improvements in early diabetic kidney disease in male rats. <b>2022</b> , 136, 1485-1511                      | 0 |
| 197 | Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications. <b>2022</b> , 23, 13320                            | 1 |
| 196 | Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease. <b>2022</b> , 30, 100309            | 0 |
| 195 | Nrf2 deficiency deteriorates diabetic kidney disease in Akita model mice. <b>2022</b> , 58, 102525  | 1 |
| 194 | Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. <b>2022</b> , 7, 216-224   | 0 |
| 193 | Single nucleotide polymorphisms in the GFR-related gene and the SNP/BNP interactions on the risk of diabetic kidney disease in Chinese Han population.                              | 0 |
| 192 | A comprehensive weighted gene co-expression network analysis uncovers potential targets in diabetic kidney disease. <b>2022</b> ,   | 0 |
| 191 | Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease. 10,              | 1 |
| 190 | Kidney function measures and cardiovascular outcomes in people with diabetes: the Hoorn Diabetes Care System cohort.  | 0 |
| 189 | Mendelian randomization study supports the casual association between serum cystatin C and risk of diabetic nephropathy. 13,  | 0 |
| 188 | Multi-Scalar Data Integration Links Glomerular Angiotensin-Tie Signaling Pathway Activation With Progression of Diabetic Kidney Disease.  | 0 |
| 187 | Anthocyanin improves kidney function in diabetic kidney disease by regulating amino acid metabolism. <b>2022</b> , 20,  | 0 |



|     |   |   |
|-----|---|---|
| 186 | Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study. <b>2022</b> , 44, 1996-2005  | 2 |
| 185 | Machine Learning Models for Data-Driven Prediction of Diabetes by Lifestyle Type. <b>2022</b> , 19, 15027   | 1 |
| 184 | Acute Helicobacter pylori Infection Prevalence Among Renal Failure Patients and Its Potential Roles with Other Chronic Diseases: A Retrospective Cohort Study. Volume 15, 6589-6599   | 0 |
| 183 | Asiatic acid attenuates tubular injury in diabetic kidney disease by regulating mitochondrial dynamics via the Nrf-2 pathway. <b>2022</b> , 154552  | 0 |
| 182 | Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. <b>2022</b> , 21, | 1 |
| 181 | Frailty, sarcopenia and diabetic kidney disease: where do we stand?.  | 0 |
| 180 | The Role of NF- $\kappa$ B and Bax/Bcl-2/Caspase-3 Signaling Pathways in the Protective Effects of Sacubitril/Valsartan (Entresto) against HFD/STZ-Induced Diabetic Kidney Disease. <b>2022</b> , 10, 2863                          | 0 |
| 179 | The Impact of Carbamylation and Anemia on HbA1c Association With Renal Outcomes in Patients With Diabetes and Chronic Kidney Disease.   | 0 |
| 178 | Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38/P53 signaling axis. <b>2023</b> , 353, 621-633  | 1 |
| 177 | Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors. <b>2022</b> , 18, 106   | 0 |
| 176 | Machine learning models for prediction of HF and CKD development in early-stage type 2 diabetes patients. <b>2022</b> , 12,   | 0 |
| 175 | The role of Mitochondrial Fission Proteins in Mitochondrial Dynamics in Kidney Disease. <b>2022</b> , 23, 14725   | 2 |
| 174 | Classifying Kidney Disease in a Vervet Model Using Spatially Encoded Contrast-Enhanced Ultrasound Perfusion Parameters. <b>2022</b> ,   | 0 |
| 173 | Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors. <b>2022</b> , 12,   | 0 |
| 172 | Resveratrol Ameliorates Kidney Injury and Fibrosis Secondary to Diabetes in Association with Inflammation and Nitrosative Stress Inhibition in Rats. <b>2022</b> , 18, 1576-1582  | 0 |
| 171 | Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action. <b>2022</b> , 25, 492-498  | 0 |
| 170 | Identifying myoglobin as a mediator of diabetic kidney disease: a machine learning-based cross-sectional study. <b>2022</b> , 12,   | 0 |
| 169 | Genome-wide association study of longitudinal urinary albumin excretion in patients with type 1 diabetes.   | 0 |

- 168 Elevated serum uric acid is not an independent risk factor for the occurrence of Type 2 diabetic kidney disease in Chinese populations. **2022**, 101, e32128 ○
- 167 Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis. ○
- 166 The harmful intestinal microbial community accumulates during DKD exacerbation and microbiome-metabolome combined validation in a mouse model. 13, ○
- 165 Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor. ○
- 164 Association between probiotic, prebiotic, and yogurt consumption and chronic kidney disease: The NHANES 2010-2020. 9, ○
- 163 The Role of Oxidative Stress-Mediated Inflammation in the Development of T2DM-Induced Diabetic Nephropathy: Possible Preventive Action of Tannins and Other Oligomeric Polyphenols. **2022**, 27, 9035 2
- 162 The rs3931283/PVT1 and rs7158663/MEG3 polymorphisms are associated with diabetic kidney disease and markers of renal function in patients with type 2 diabetes mellitus. ○
- 161 High blood sugar may blunt the protective benefits of FXR for the survival of renal medullary collecting duct cells in response to hypertonic stress. ○
- 160 Ellagic Acid Inhibits TGF $\beta$ /Smad-Induced Renal Fibrosis in Diabetic Kidney Injury. ○
- 159 External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study. ○
- 158 The membrane-associated protein 17 (MAP17) is upregulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy. ○
- 157 Epigenetics and endoplasmic reticulum in podocytopathy during diabetic nephropathy progression. 13, ○
- 156 Diabetic Kidney Care Redefined with a New Way into Remission. **2022**, ○
- 155 A retrospective case - control study for assessing the risk factors for development of Diabetic Kidney Disease among people with Type 2 Diabetes in Tamil Nadu and Puducherry. ○
- 154 Estimation of Glomerular Filtration Rate for diabetic patients by using Simplified Modification of Diet in Renal Disease (MDRD), Southwest Ethiopia. ○
- 153 A Retrospective Study of the Perioperative Period Management of Joint Arthroplasty in Patients with Chronic Kidney Disease. ○
- 152 Garlic (*Allium sativum* L.) in diabetes and its complications: Recent advances in mechanisms of action. 1-51 ○
- 151 *Moringa oleifera* impedes protein glycation and exerts reno-protective effects in streptozotocin-induced diabetic rats. **2022**, 116117 ○

- 150 Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors. **2022**, 11, 3913 ○
- 149 Risk factors of chronic kidney disease among type 2 diabetic patients with longer duration of diabetes. 13, ○
- 148 Predictors of microalbuminuria and its relationship with glycemic control among Type 2 diabetic patients of Jazan Armed Forces Hospital, southwestern Saudi Arabia. **2022**, 22, ○
- 147 The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease. 13, ○
- 146 Glucosamine inhibits extracellular matrix accumulation in experimental diabetic nephropathy. 9, ○
- 145 Dynein-mediated trafficking, a new mechanism of diabetic podocytopathy. 10.34067/KID.0006852022 ○
- 144 Urinary N-acetyl-β-D-glucosaminidase-creatinine ratio is a valuable predictor for advanced diabetic kidney disease. ○
- 143 GTS-21, a selective alpha7 nicotinic acetylcholine receptor agonist, ameliorates diabetic nephropathy in Leprdb/db mice. **2022**, 12, ○
- 142 SMART-Finder - Identification of patients with elevated urine-albumine-creatinine-ratio levels in a type 2 diabetes mellitus cohort based on self-reported data via smartphone app in an observational study (Preprint). ○
- 141 Clinical efficacy and safety of warm acupuncture in the treatment of type 2 diabetic kidney disease: A protocol of a randomized controlled trial. **2022**, 101, e32034 ○
- 140 Association between Diabetic Kidney Disease and Diabetic Foot Ulceration. ○
- 139 Interactive effects of intrinsic capacity and obesity on the KDIGO chronic kidney disease risk classification in older patients with type 2 diabetes mellitus. **2023**, 15, ○
- 138 Proximal tubule-derived exosomes contribute to mesangial cell injury in diabetic nephropathy via miR-92a-1-5p transfer. **2023**, 21, ○
- 137 Research Progress of Mineralocorticoid Receptor Antagonists on Diabetic Kidney Disease. **2023**, 13, 427-435 ○
- 136 Effects of antioxidants on diabetic kidney diseases: mechanistic interpretations and clinical assessment. **2023**, 18, ○
- 135 Molecular profiling of urinary extracellular vesicles in chronic kidney disease and renal fibrosis. 13, ○
- 134 Research Progress of Ferroptosis in Diabetes Mellitus and Related Complications. **2022**, 12, 11720-11726 ○
- 133 The relationship between serum γ-glutamyltransferase (GGT) and diabetic nephropathy in patients with type 2 diabetes mellitus: a cross-sectional study. ○

- 132 Simultaneous blockade of VEGF-B and IL-17A ameliorated diabetic kidney disease by reducing ectopic lipid deposition and alleviating inflammation response. **2023**, 9, ○
- 131 Baseline anxiety disorders are associated with progression of diabetic kidney disease in type 2 diabetes. **2023**, 45, ○
- 130 Effect of frailty, physical performance, and chronic kidney disease on mortality in older patients with diabetes : a retrospective longitudinal cohort study. **2023**, 15, ○
- 129 Diabetes Mellitus: Quantum MicroRNA Language with Artificial Intelligence (MIRAI) as an Early Diagnostic Tool for Type 2 Diabetes Mellitus for Sustainable Healthcare. **2023**, 79-101 ○
- 128 The Effect of the Extra Virgin Olive Oil Minor Phenolic Compound 3',4'-Dihydroxyphenylglycol in Experimental Diabetic Kidney Disease. **2023**, 15, 377 ○
- 127 Impact of albuminuria on the various causes of death in diabetic patients: a nationwide population-based study. **2023**, 13, ○
- 126 PLVAP as an Early Marker of Glomerular Endothelial Damage in Mice with Diabetic Kidney Disease. **2023**, 24, 1094 ○
- 125 Sample Size Calculation in Genetic Association Studies: A Practical Approach. **2023**, 13, 235 1
- 124 Incidence, Severity, and Presentation of Type 2 Diabetes in Youth During the First and Second Year of the COVID-19 Pandemic. ○
- 123 Network-based identification and prioritization of key transcriptional factors of diabetic kidney disease. **2023**, 21, 716-730 ○
- 122 Risk of cardiovascular disease, death, and renal progression in diabetes according to albuminuria and estimated glomerular filtration rate. **2023**, 101420 ○
- 121 Syringaresinol protects against diabetic nephropathy by inhibiting pyroptosis via NRF2-mediated antioxidant pathway. ○
- 120 Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity. **2023**, 170955 ○
- 119 Gliflozins Have an Anti-Inflammatory Effect on Renal Proximal Tubular Epithelial Cells in a Diabetic and Inflammatory Microenvironment In Vitro. **2023**, 24, 1811 ○
- 118 Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population. **2023**, 29, 80-89 ○
- 117 Efficacy and safety of Keluoxin capsule in combination with Western medicine for diabetic kidney disease: A systematic review and meta-analysis. 13, ○
- 116 Agomelatine improves streptozotocin-induced diabetic nephropathy through melatonin receptors/SIRT1 signaling pathway. **2023**, 115, 109646 1
- 115 YY1 was indispensable for the alleviation of quercetin on diabetic nephropathy-associated tubulointerstitial inflammation. **2023**, 111, 154659 ○

- 114 Process of Glucose Increases Rather Than Constant High Glucose Was the Main Cause of Abnormal Glucose Induced Glomerulus Epithelial Cells Inflammatory Response. **2023**, 24, 600 ○
- 113 A comprehensive weighted gene co-expression network analysis uncovers potential targets in diabetic kidney disease. **2023**, 10, 359-368 ○
- 112 Risk prediction of nephropathy by integrating clinical and genetic information among adult patients with type 2 diabetes. ○
- 111 The Role of Esm-1 in Diabetic Kidney Disease: More Than Just a Biomarker. **2022**, 3, 1998-2000 ○
- 110 Expression of Ferroptosis-Related Genes is Correlated with Immune Microenvironment in Diabetic Kidney Disease. Volume 15, 4049-4064 ○
- 109 What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances. **2023**, 24, 570 ○
- 108 Association of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio with Diabetic Kidney Disease in Chinese Patients with Type 2 Diabetes: A Cross-Sectional Study. Volume 18, 1157-1166 ○
- 107 Tratamiento renal sustitutivo con diálisis en el paciente diabético. **2022**, 25, 300-308 ○
- 106 Identification of key genes and biological regulatory mechanisms in diabetic nephropathy: Meta-analysis of gene expression datasets. **2023**, ○
- 105 Identification of ULK1 as a novel mitophagy-related gene in diabetic nephropathy. 13, ○
- 104 Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. 14, ○
- 103 Urinary Extracellular Vesicles in Chronic Kidney Disease: From Bench to Bedside?. **2023**, 13, 443 ○
- 102 Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy. **2023**, 13, 473 ○
- 101 Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis. 14, ○
- 100 Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. **2023**, 10, 205435812211505 1
- 99 QiHuangYiShen Granules Modulate the Expression of LncRNA MALAT1 and Attenuate Epithelial-Mesenchymal Transition in Kidney of Diabetic Nephropathy Rats. **2023**, 2023, 1-11 ○
- 98 Nephron deficit and low podocyte density increase risk of albuminuria and glomerulosclerosis in a model of diabetes. **2023**, 11, ○
- 97 High Glucose-Induced Kidney Injury via Activation of Necroptosis in Diabetic Kidney Disease. **2023**, 2023, 1-14 1

- 96 The Risk of Renal Outcome of Metabolic Syndrome independent of Diabetes in Patients with CKD stage 1 to 4: The ICKD database. ○
- 95 Beyond Blood Glucose and Blood Pressure Control in Type 2 Diabetes: Alternative Management Strategies to Prevent the Development and Progression of CKD. **2023**, 14, 215013192311535 ○
- 94 Polysaccharide H-1-2 Ameliorates High Glucose-Induced Podocyte Dysfunction by Suppressing Epithelial-to-Mesenchymal Transition via Restoration of SIRT1 &in vivo& and &in vitro&. **2023**, ○
- 93 Microarray expression profile of exosomal circRNAs from high glucose stimulated human renal tubular epithelial cells. ○
- 92 The Role of Histone Modifications in the Pathogenesis of Diabetic Kidney Disease. **2023**, 24, 6007 ○
- 91 Logic-Based Modeling of Inflammatory Macrophage Crosstalk with Glomerular Endothelial Cells in Diabetic Kidney Disease. ○
- 90 mTOR signaling in renal ion transport. ○
- 89 Integrated analysis for treatment scheme of sodium-glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study. **2023**, 13, ○
- 88 Bioinformatics analysis of potential key ferroptosis-related genes involved in tubulointerstitial injury in patients with diabetic nephropathy. **2023**, 45, ○
- 87 Protease-activated receptors in kidney diseases: A comprehensive review of pathological roles, therapeutic outcomes and challenges. **2023**, 377, 110470 ○
- 86 Yishen Tongluo formula alleviates diabetic kidney disease through regulating Sirt6/TGF- $\beta$ /Smad2/3 pathway and promoting degradation of TGF- $\beta$ . **2023**, 307, 116243 ○
- 85 Novel clinical associations between time in range and microangiopathies in people with type 2 diabetes mellitus on hemodialysis. **2023**, 37, 108470 ○
- 84 Macrovascular and microvascular type 2 diabetes complications are interrelated in a mouse model. **2023**, 37, 108455 ○
- 83 Relaxin elicits renoprotective actions accompanied by increasing bile acid levels in streptozotocin-induced diabetic mice. **2023**, 162, 114578 ○
- 82 GYY4137, a H<sub>2</sub>S donor, ameliorates kidney injuries in diabetic mice by modifying renal ROS-associated enzymes. **2023**, 162, 114694 ○
- 81 Inhibition of N-glycosylation by glucosamine hydrochloride inhibits TGF- $\beta$ -induced LOXL2 secretion. ○
- 80 Advances in Chronic Kidney Disease in Africa. **2023**, 13, 4924 ○
- 79 Antidiabetic and hepato-renal protective effects of medicinal plants in STZ induced diabetic rats. **2023**, 84, ○

- 78 Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease. **2023**, 942, 175521 ○
- 77 Evaluating the potential of tauroursodeoxycholic acid as add-on therapy in amelioration of streptozotocin-induced diabetic kidney disease. **2023**, 942, 175528 ○
- 76 Amelioration of diabetic kidney injury with dapagliflozin is associated with suppressing renal HMGB1 expression and restoring autophagy in obese mice. **2023**, 37, 108409 ○
- 75 Estudio piloto de seguimiento en pacientes con enfermedad renal diabética mediante la aplicación NORA. **2023**, ○
- 74 Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidney. **2023**, 943, 175560 ○
- 73 MIR503HG: A potential diagnostic and therapeutic target in human diseases. **2023**, 160, 114314 ○
- 72 Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. **2023**, 103, 772-781 ○
- 71 Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice. **2023**, 37, 108411 ○
- 70 Jiedu Tongluo Baoshen formula enhances renal tubular epithelial cell autophagy to prevent renal fibrosis by activating SIRT1/LKB1/AMPK pathway. **2023**, 160, 114340 ○
- 69 Transcriptomics-proteomics Integration reveals alternative polyadenylation driving inflammation-related protein translation in patients with diabetic nephropathy. **2023**, 21, ○
- 68 The impact of oxidative stress-induced mitochondrial dysfunction on diabetic microvascular complications. 14, 1
- 67 Free Triiodothyronine predicts the risk of developing Diabetic Kidney Disease. ○
- 66 Electrocardiogram abnormalities and renal impairment in patients with type 2 diabetes mellitus: A healthcare facilities-based cross-sectional study in Dang district of Nepal. **2023**, 14, 602-613 ○
- 65 Potentially inappropriate medication among older patients with diabetic kidney disease. 14, ○
- 64 A Multifactorial Risk Score System for the Prediction of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus. Volume 16, 385-395 ○
- 63 Hyperuricemia Predicts the Progression of Type 2 Diabetic Kidney Disease in Chinese Patients. **2023**, 14, 581-591 ○
- 62 Breviscapine alleviates podocyte injury by inhibiting NF- $\kappa$ B/NLRP3-mediated pyroptosis in diabetic nephropathy. 11, e14826 ○
- 61 Pediatric Diabetic Nephropathy: Novel Insights from microRNAs. **2023**, 12, 1447 ○

- 60 The Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy Disease: An Update. **2023**, 13, 539 ○
- 59 Effect of glucuronic acid on inducing self-assembly of Au nanoflowers@glucuronic acid on carbon cloth for non-enzymatic glucose sensing. **2023**, 29, 101388 ○
- 58 Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users. ○
- 57 Network Pharmacology and Bioinformatics Methods Reveal the Mechanism of Sishenwan in the Treatment of diabetic nephropathy. ○
- 56 Efficacy of traditional Chinese medicine injection for diabetic kidney disease: A network meta analysis and systematic review. 14, ○
- 55 Identification of Patients With Elevated Urine Albumin-to-Creatinine Ratio Levels in a Type 2 Diabetes Mellitus Cohort Based on Data Submitted by Patients via a Smartphone App (SMART-Finder): Protocol for an Observational Study. 12, e44996 ○
- 54 Identification and validation of immune and oxidative stress-related diagnostic markers for diabetic nephropathy by WGCNA and machine learning. 14, ○
- 53 Development and validation of a risk prediction model for early diabetic peripheral neuropathy based on a systematic review and meta-analysis. 11, ○
- 52 Luteolin improves nephropathy in hyperglycemic rats through anti-oxidant, anti-inflammatory, and anti-apoptotic mechanisms. **2023**, 102, 105461 ○
- 51 Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study. **2023**, Publish Ahead of Print, ○
- 50 Cell surface GRP78 regulates TGF $\beta$ -mediated profibrotic responses via TSP1 in diabetic kidney disease. 14, ○
- 49 A drug utilisation pattern in non-dialysis patients of diabetic nephropathy in a government-run tertiary care hospital in South-Asia. **2023**, ○
- 48 Association of S19W polymorphism in APOA5 gene and serum lipid levels in patients with type 2 diabetic nephropathy. **2022**, ○
- 47 Placental Mesenchymal Stem Cells Alleviate Podocyte Injury in Diabetic Kidney Disease by Modulating Mitophagy via the SIRT1-PGC-1 $\alpha$ -TFAM Pathway. **2023**, 24, 4696 ○
- 46 miRNA Signature of Urine Extracellular Vesicles Shows the Involvement of Inflammatory and Apoptotic Processes in Diabetic Chronic Kidney Disease. ○
- 45 The Association Between Microalbuminuria and QTc Prolongation in Patients With Type 2 Diabetes Mellitus: A Single-Centre Study From South India. **2023**, ○
- 44 Broadening horizons in mechanisms, management, and treatment of diabetic kidney disease. **2023**, 190, 106710 ○
- 43 The Proteome of Circulating Large Extracellular Vesicles in Diabetes and Hypertension. **2023**, 24, 4930 ○



- 42 Four missense genetic variants in CUBN are associated with higher levels of eGFR in non-diabetes but not in diabetes mellitus or its subtypes: A genetic association study in Europeans. 14, ○
- 41 Identification of diagnostic markers related to oxidative stress and inflammatory response in diabetic kidney disease by machine learning algorithms: Evidence from human transcriptomic data and mouse experiments. 14, ○
- 40 The concordance and discordance of diabetic kidney disease and retinopathy in patients with type 2 diabetes mellitus: A cross-sectional study of 26,809 patients from 5 primary hospitals in China. 14, ○
- 39 Pathomechanismen der chronischen Nierenschädigung bei Diabetes und anderen Begleiterkrankungen. ○
- 38 Low dose Taxol ameliorated renal fibrosis in mice with diabetic kidney disease by downregulation of HIPK2. **2023**, 320, 121540 ○
- 37 Analysis of gene expression and use of connectivity mapping to identify drugs for treatment of human glomerulopathies. 10, ○
- 36 CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. **2023**, 22, ○
- 35 The Role of Ketone Bodies in Various Animal Models of Kidney Disease. **2023**, 4, 236-249 ○
- 34 The effects of using Tempeh as a supplement for type 2 diabetes. ○
- 33 The Fat Kidney. ○
- 32 Diabesity and the Kidney. **2023**, 168-207 ○
- 31 A genome-wide association study identifies a possible role for cannabinoid signalling in the pathogenesis of diabetic kidney disease. **2023**, 13, ○
- 30 THE ROLE OF LIPID METABOLISM IN THE DEVELOPMENT OF ENDOTHELIAL DYSFUNCTION IN DIABETIC NEPHROPATHY. **2023**, 19, 126 ○
- 29 Identifying Key Genes for Diabetic Kidney Disease by Bioinformatics Analysis. ○
- 28 Diabetic peripheral neuropathy is associated with diabetic kidney disease and cardiovascular disease □The Silesia Diabetes-Heart Project. **2023**, 101726 ○
- 27 Diabetic nephropathy with primary membranous nephropathy: A case report. **2022**, 2, 52-55 ○
- 26 The Role of MicroRNA in the Pathogenesis of Diabetic Nephropathy. **2023**, 24, 6214 ○
- 25 Histological findings of diabetic kidneys transplanted in non-diabetic recipients: a case series. ○

- 24 Single-cell RNA and transcriptome sequencing profiles identify immune-associated key genes in the development of diabetic kidney disease. 14, ○
- 23 LIFEHOUSE Functional Nutrition Examination (Physical Exam, Anthropometrics, and Selected Biomarkers) Informs Personalized Wellness Interventions. **2023**, 13, 594 ○
- 22 Advances in the Study of Obesity and Diabetic Vascular Complications. **2023**, 13, 4686-4693 ○
- 21 Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. **2023**, 365-396 ○
- 20 Association between lower phase angle and chronic kidney disease progression in type 2 diabetes patients. **2023**, 52, 125-134 ○
- 19 Management of diabetic kidney disease: where do we stand?: A narrative review. **2023**, 102, e33366 ○
- 18 Study of Homocysteine, SDMA, ADMA, UMOD, AVP, and KIM-1 in serum of chronic renal disease patients suffering from Type-2 diabetes in Basra Province. **2023**, 16, 503-508 ○
- 17 Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges. **2023**, 32, 096368972311642 ○
- 16 XOR risk variants drive diabetic kidney disease. ○
- 15 AG1024, an IGF-1 receptor inhibitor, ameliorates renal injury in rats with diabetic nephropathy via the SOCS/JAK2/STAT pathway. **2023**, 18, ○
- 14 Identification of Biomarkers Associated with Diagnosis of Diabetic Nephropathy Patients Based on Bioinformatics and Machine Learning. ○
- 13 Independent risk factors of rapid glomerular filtration rate decline in patients with type 2 diabetes with preserved kidney function and normoalbuminuria: A multicenter cohort study. ○
- 12 Diabetic Kidney Disease. **2023**, ○
- 11 Clinical Relevance of lncRNA and Mitochondrial Targeted Antioxidants as Therapeutic Options in Regulating Oxidative Stress and Mitochondrial Function in Vascular Complications of Diabetes. **2023**, 12, 898 ○
- 10 The Role of L-Carnitine in Kidney Disease and Related Metabolic Dysfunctions. **2023**, 3, 178-191 ○
- 9 The Association between Plant-Based Dietary Index and Odds of Diabetic Nephropathy in Women: A Case-Control Study. ○
- 8 Sex-Related Aspects in Diabetic Kidney Disease An Update. **2023**, 12, 2834 ○
- 7 Chronic Kidney Disease. **2023**, 327-346 ○

- 6 Clinical outcomes in patients with type 2 diabetes mellitus-related kidney disease: A Jordanian population cohort study. **2023**, 37, 108478
- 5 Screening and identification of key biomarkers in diabetic kidney disease and its complications: Evidence from bioinformatics and next generation sequencing data analysis.
- 4 Klotho $\beta$  impact on diabetic nephropathy and its emerging connection to diabetic retinopathy. 14,
- 3 Preliminary study of the interactive effects of coronary heart disease and lacunar infarction on renal function in patients with type 2 diabetes mellitus by gender. **2023**, 108477
- 2 Finerenone: pharmacological profile. **2023**, 37, 29-32
- 1 Impact of Baseline Clinical Variables on SGLT2i $\beta$  Antiproteinuric Effect in Diabetic Kidney Disease. **2023**, 13, 1061